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Background: Acute otitis media (AOM) is a common reason for primary care consultations and antibiotic
prescribing in children. Options for improved pain control may influence antibiotic prescribing and consumption.
Objective: The Children’s Ear Pain Study (CEDAR) investigated whether or not providing anaesthetic–analgesic
ear drops reduced antibiotic consumption in children with AOM. Secondary objectives included pain
control and cost-effectiveness.
Design: A multicentre, randomised, parallel-group (two-group initially, then three-group) trial.
Setting: Primary care practices in England and Wales.
Participants: 1- to 10-year-old children presenting within 1 week of suspected AOM onset with ear pain
during the preceding 24 hours and not requiring immediate antibiotics. Participating children were logged
into the study and allocated using a remote randomisation service.
Interventions: Two-group trial – unblinded comparison of anaesthetic–analgesic ear drops versus usual
care. Three-group trial – blinded comparison of anaesthetic–analgesic ear drops versus placebo ear drops
and unblinded comparison with usual care.
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Main outcome measures: The primary outcome measure was parent-reported antibiotic use by the child
over 8 days following enrolment. Secondary measures included ear pain at day 2 and NHS and societal
costs over 8 days.
Results: Owing to a delay in provision of the placebo drops, the recruitment period was shortened and
most participants were randomly allocated to the two-group study (n = 74) rather than the three-group
study (n = 32). Comparing active drops with usual care in the combined two-group and three-group
studies, 1 out of 39 (3%) children allocated to the active drops group and 11 out of 38 (29%) children
allocated to the usual-care group consumed antibiotics in the 8 days following enrolment [unadjusted odds
ratio 0.09, 95% confidence interval (CI) 0.02 to 0.55; p = 0.009; adjusted for delayed prescribing odds
ratio 0.15, 95% CI 0.03 to 0.87; p = 0.035]. A total of 43% (3/7) of patients in the placebo drops group
consumed antibiotics by day 8, compared with 0% (0/10) of the three-group study active drops groups
(p = 0.051). The economic analysis of NHS costs (£12.66 for active drops and £11.36 for usual care) leads to
an estimated cost of £5.19 per antibiotic prescription avoided, but with a high degree of uncertainty. A
reduction in ear pain at day 2 in the placebo group (n= 7) compared with the active drops group (n= 10)
(adjusted difference in means 0.67, 95% CI –1.44 to 2.79; p= 0.51) is consistent with chance. No adverse
events were reported in children receiving active drops.
Limitations: Estimated treatment effects are imprecise because the sample size target was not met.
It is not clear if delayed prescriptions of an antibiotic were written prior to randomisation. Few children
received placebo drops, which hindered the investigation of ear pain.
Conclusions: This study suggests that reduced antibiotic use can be achieved in children with AOM by
combining a no or delayed antibiotic prescribing strategy with anaesthetic–analgesic ear drops. Whether or
not the active drops relieved ear pain was not established.
Future work: The observed reduction in antibiotic consumption following the prescription of ear drops
requires replication in a larger study. Future work should establish if the effect of ear drops is due to
pain relief.
Trial registration: Current Controlled Trials ISRCTN09599764.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 34.
See the NIHR Journals Library website for further project information. Alastair D Hay was funded by a NIHR
Research Professorship (funding identifier NIHR-RP-02-12-012).
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Plain English summary
Ear infections are common in children < 10 years of age, with 40% of these children suffering from anear infection at least once per year. During the infection, germs multiply in the confined space of the
middle ear, resulting in a build-up of pressure that pushes on and stretches the ear drum. This causes
severe pain and distress to the child, which in turn leads to disrupted family life.
Although there is world-class evidence showing that antibiotics do not help, and the National Institute
for Health and Care Excellence advises against their use, > 85% of UK children with middle ear infections
(acute otitis media) are prescribed an antibiotic, which is a higher percentage than for any other childhood
infection. Antibiotics do not treat the child’s pain and, in most cases, they do not help to treat the
infection (because many ear infections are caused by viruses that do not respond to antibiotics), but they
can cause side effects (such as diarrhoea) and increase the problem of antibiotic resistance, which is a
major public health concern.
The Children’s Ear Pain Study (CEDAR) wanted to find out whether or not painkilling ear drops
[benzocaine–phenazone otic solution (Auralgan®) currently manufactured by Pfizer Consumer Healthcare
(Pfizer Inc., New York, NY USA)] can, by treating children’s ear pain, reduce the number of parents giving
their children antibiotics for acute otitis media. Children were given the painkilling drops, placebo (dummy)
drops or usual care. The study found that, if the children were given the painkilling drops, significantly
fewer of them were given antibiotics.
Unfortunately, there were not enough children who took part in the study to change advice on how
doctors treat ear infections. However, these results suggest that ear drops help reduce unnecessary
antibiotic use and should be investigated in a further larger study.
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Scientific summary
Background
Acute otitis media (AOM) is a common, painful condition of childhood that has an impact on the family
because of disrupted sleep and time off work and school. Primary care consultation and antibiotics have been
the mainstay of management; one UK study found that between 80% and 84% of children presenting to
primary care with AOM were prescribed an antibiotic during the years 1995–2011 (Williamson I, Benge S,
Mullee M, Little P. Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance:
a case-linked cohort study. Br J Gen Pract 2006;56:170–5). This is despite the available evidence of benefit
being restricted to children < 2 years old with bilateral AOM, and those with otorrhoea, leading the National
Institute for Health and Care Excellence (NICE) to conclude that these are the only children warranting a
same-day full-course antibiotic treatment. For other children, the use of a ‘wait-and-see’ strategy, with or
without a delayed prescription for an antibiotic, has been shown to be safe in terms of treatment failure and
in the frequency of complications of AOM. Selective antibiotic prescribing in AOM is also recommended by
other national guidelines, including the American Academy of Family Physicians and American Academy of
Pediatrics, Dutch College of General Practitioners, Scottish Intercollegiate Guideline Network and French
Health Products Safety Agency.
Judicious use of antibiotics seeks not only to counter the risks of antibiotic side effects (such as diarrhoea,
rashes and anaphylaxis) but to also counter the risk of increasing antibiotic-resistant bacterial strains,
which have been shown to increase substantially after antibiotic use. In view of AOM’s prevalence, and the
high level of associated antibiotic use, strategies to facilitate a reduction in antibiotic use in this condition
in the UK are urgently required. Anaesthetic–analgesic ear drops are widely used in some countries and,
if effective for controlling ear pain, could reduce dependence on antibiotics. However, there is little
evidence regarding their effectiveness as an analgesic and no evidence on how their use affects antibiotic
consumption.
Objectives
The primary aim of the study was to determine if providing topical anaesthetic–analgesic drops
[benzocaine–phenazone otic solution (Auralgan®), currently manufactured by Pfizer Consumer Healthcare]
leads to a reduction in antibiotic consumption within the first 8 days of AOM diagnosis.
The secondary objectives were to answer the following questions:
l Are anaesthetic–analgesic ear drops more effective than placebo (key secondary question) and usual
care in controlling AOM ear pain?
l Are children and their parents satisfied with using ear drops?
l Are anaesthetic–analgesic ear drops cost-effective?
l Do the drops improve the child’s quality of life?
l What are the parents’ beliefs and expectations in relation to AOM and its treatment?
Methods
The Children’s Ear Pain Study (CEDAR) was a multicentre, randomised three-group (anaesthetic–analgesic
drops, placebo drops and usual care) randomised controlled trial (RCT). Owing to investigational medicinal
product (IMP) supply problems, recruitment was initially to a two-group (anaesthetic–analgesic drops vs.
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usual care) RCT. General practice surgeries in the primary care research network within the areas of Bristol,
Cardiff and Southampton agreed to participate. The study was co-ordinated by the Bristol study centre.
Children were eligible if they met all of the following criteria:
l They were aged between 12 months and 9 years.
l They presented within 1 week of suspected AOM onset.
l They had parent-reported ear pain in 24 hours pre enrolment.
l They had clinician diagnosis of AOM.
l They were immunocompetent.
l A clinician was willing to use a NICE-recommended ‘no’ oral antibiotic prescribing strategy or a
‘delayed’ oral antibiotic prescribing strategy (as per NICE guidelines) [National Institute for Health and
Care Excellence. Respiratory Tract Infections (Self-Limiting): Prescribing Antibiotics. Clinical Guideline
CG69. London: National Institute for Health and Care Excellence; 2008].
l A parent or legal guardian is able to give informed consent.
Children were excluded from the study if they:
l were severely ill
l were unable to meet NICE delayed or no antibiotic for AOM criteria
l were at a high risk of serious complications
l were unfit to use topical ear drops
l were allergic to the components of the active drop
l had an alternative cause for ear ache
l required antibiotics for a coexisting condition.
The IMP for this trial was a benzocaine–phenazone otic solution (Auralgan). This is an oil-based, combined
local anaesthetic (benzocaine) and analgesic (phenazone, also known in the USA as antipyrine) ear drop.
One millilitre contains 14 mg (1.4%) of benzocaine and 54mg (5.4%) of phenazone suspended in a glycerine-
based liquid along with a preservative (hydroxyquinoline sulphate). Despite an absence of published evidence
of effectiveness, it is available as a pharmacy medicine in Australia and has been marketed since 1947 under
Auralgan and other brand names. For this trial we intended to test Auralgan sold in 15-ml bottles. The placebo
was glycerine (Albany Molecular Research Ltd, Glasgow, UK), with identical packaging to the active drops.
Randomisation was stratified by centre in blocks of 30 packs, each block having the packs arranged in a
random and consecutively numbered sequence. The IMP supplier provided the pharmacy with medicine
packs which had each been prelabelled with the patient identifier (ID) and medicine pack ID numbers.
Each pack contained two bottles of active medicine, two bottles of placebo medicine or no bottles but a
non-medicinal item of similar weight. Patients were enrolled by their general practitioner (GP) or research
nurse who, at the stage of enrolment, was unaware of the contents of the next treatment pack in the
sequence (maintaining allocation concealment). When the informed consent process was completed
and signed, the trial pack was opened and allocation to active drops, placebo drops or no drops was
confirmed. It was not clear if antibiotic prescribing decisions were made before or after opening the pack.
During the 8 days following randomisation, parents completed a daily questionnaire that asked about
antibiotic use; ear pain on days 1 and 2; analgesic (e.g. ibuprofen or paracetamol) consumption; symptom
presence and severity (e.g. episodes of crying, disturbed sleep and fever); adverse events; new or worsening
symptoms (asked only on last day); satisfaction with, and opinion of, treatment allocation and future
intention to use drops; costs; preference-based quality of life using the CHU-9D questionnaire and child’s
quality of life using the OMQ-14 questionnaire.
The net incremental costs to the NHS and society of using active ear drops compared with usual care (no
drops) in the short (8 days) and medium term (3 months) were assessed. NHS resource use (e.g. antibiotic
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or analgesic use, GP visits) and societal costs (school/nursery absences, parent lost productivity and other
family expenses) were reported by parents in the 8-day questionnaire. Medium-term NHS resource use was
collated from a review of the child’s GP records.
All parents agreeing to participate were asked, at the time of consent, if they were willing to be contacted
about taking part in a telephone interview. In-depth telephone interviews were conducted with parents
14 days afer randomisation. Lines of questioning focused on views and experiences of the disease, its diagnosis,
treatment and recovery, information and support needs, and views and experiences of participation within
the trial. Interviews also explored the potential implications of making the CEDAR drops available over the
counter, which means that the costs will shift from the NHS to the individual. Health-care professionals were
to be interviewed to explore their views and experiences of the trial, information and support needs, and their
attitudes to the future implementation of treatments. A flexible interview topic guide was used to ensure
that primary issues were covered during all interviews, but without dictating data collection. The interviewer
used open-ended questioning techniques to elicit participants’ experiences and views of key events, and
participants were asked to provide examples.
Based on existing literature, an antibiotic consumption rate of 80% was assumed for the usual treatment
(no drop) group. To show an absolute 20% reduction in antibiotic consumption from a baseline of 80%
(thought likely to have important effects on antimicrobial resistance), with 90% power at the 5% significance
level, the trial would require 119 patients in each group. Allowing for a 20% loss to follow-up, the target
sample size was adjusted to 149 patients in each group.
The primary outcome of antibiotic consumption was analysed using logistic regression, adjusting for
whether or not the child had received a delayed antibiotic script at baseline. Secondary outcome measures
were compared between the study groups using an appropriate regression model. Health economic analysis
was undertaken primarily for active ear drops versus usual care comparison of the NHS, family and societal
cost per antibiotic consumption avoided during the AOM episode. The qualitative interview data were
subjected to thematic analysis using an inductive approach to identify major themes.
Results
Owing to a delay in procurement of a suitable placebo, the study (especially the three-group study) was
delayed and ultimately had to be closed prior to achieving recruitment targets and prior to collecting
3-month follow-up measures. A total of 74 (active drops, n = 38; and usual care, n = 36) patients were
recruited into the two-group study and 32 (active drops, n = 12; placebo drops, n = 10; and usual care,
n = 10) were recruited into the three-group study between October 2016 and June 2017. Among patients
allocated between anaesthetic–analgesic ear drops and usual care, the only apparent baseline difference
was delayed antibiotic prescribing in 11% of the usual-care group and 31% of the active drop group.
More differences were expected to occur by chance in the three-group study owing to the modest sample
size; differences were apparent in sex, accompanying adult’s age and employment status, living in an area
of deprivation, breastfeeding status at 3 months, episodes of distress/crying and disturbed sleep.
In the two-group study, 1 out of 29 (3%) and 9 out of 30 (30%) children in the active drop and usual-care
groups, respectively, consumed antibiotics. In the three-group study, the corresponding numbers were
0 out of 10 (0%) and 2 out of 8 (25%) children. Combining data from the two-group and three-group
studies gives pooled estimates of the odds ratio, comparing active drops with usual care, of 0.09
[unadjusted, 95% confidence interval (CI) 0.02 to 0.55; p = 0.009] and 0.15 (adjusted for prescription of
delayed antibiotic at recruitment, 95% CI 0.03 to 0.87; p = 0.035).
The mean (standard deviation) parent-reported ear pain scores at day 2 were 3.10 points (2.23), 2.14 points
(1.07) and 5.00 points (1.73) in the active drops, placebo drops and usual-care groups of the three-group
study, respectively. Compared with placebo drops (n = 7 children), slightly greater ear pain was apparent in
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the active drop group (n = 10; adjusted difference in means 0.67; 95% CI –1.44 to 2.79), although this
difference could have arisen by chance.
There were no differences seen in the use of analgesic consumption or illness duration, but overall
symptom burden was slightly reduced in the active group compared with both placebo and usual-care
groups. Health economic analysis revealed a statistically significant intergroup difference in antibiotic costs
of £0.38 (p = 0.01) but the overall health-care costs associated with the AOM were similar at £75.07 and
£76.92 in the active and usual-care groups, respectively.
There was a single, unrelated, serious adverse event (breathing problems) in the usual-care group.
We found no difference in reporting of adverse events between groups.
Three interviews were conducted with participating trial parents. Key findings include that parents:
l felt that the trial was a good idea and were happy for their child to participate
l described that wanting to help relieve their child’s ear pain was the main reason for consulting
l did not express any preconceptions about the need for antibiotics
l spoke positively about the trial drops and stated that they would be happy to purchase the drops over
the counter from a pharmacy, provided that pharmacist advice was available.
Conclusions
This study has provided evidence that anaesthetic–analgesic ear drops significantly reduce antibiotic
consumption in childhood otitis media. The key weakness of this study is the small sample size and the
consequent low statistical power to detect a true effect of the intervention. The small sample size for both
the quantitative and qualitative aspects of this study resulted from a much shorter recruitment period than
was planned. Despite this, CEDAR provides evidence of a substantial treatment effect in reducing antibiotic
consumption, possibly mediated by reduced antibiotic prescribing. The study was not able to establish if
reduced antibiotic consumption was achieved by a reduction in ear pain. Early study closure also prevented
qualitative interview completion and the collection of 3-month follow-up data. Finally, there was lower
than predicted antibiotic consumption in all study groups, perhaps suggesting that the participating GPs
and parents were more motivated than the norm to reduce antibiotic use.
The premise of the study was the importance of tackling antibiotic resistance by reducing unnecessary
antibiotic use in AOM. This study suggests that substantial reduction in antibiotic use might be achieved in
AOM-affected children by combining a no or delayed prescribing strategy with anaesthetic–analgesic ear
drops. There were no adverse events in the active treatment group. Importantly, the parents interviewed
expressed their willingness to obtain the drops over the counter, with pharmacist guidance. Replication in
a study with larger sample size would allow more confidence in informing clinical guidelines with these
findings, would ensure the safety of the intervention over a longer follow-up period and, by establishing
the mechanism by which antibiotic use is reduced, would allow refinements to the intervention.
Trial registration
This trial is registered as ISRCTN09599764.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR). Alastair D Hay was funded by a NIHR Research Professorship (funding
identifier NIHR-RP-02-12-012).
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Chapter 1 Introduction
Structure of this report
In this chapter, the rationale for reducing antibiotic prescriptions by treating ear pain in acute otitis media
(AOM) with anaesthetic–analgesic is presented. Chapter 2 describes the study population and gives details
of the interventions being compared and the study design. Chapter 3 presents the results of the study,
followed by discussion and conclusions in Chapter 4.
Background
There is broad agreement that a high proportion of prescriptions for antibiotics are unjustified1,2 and likely to
be harmful given the clear relationship between primary care prescribed antibiotics and bacterial resistance.3
Furthermore, resistant bacteria are transmitted to social contacts, which is a problem with young children,
who are unaware of hygiene conventions and who have high contact rates with other children, parents
and grandparents.4,5
In September 2013, the Department of Health and Social Care published the UK Five Year Antimicrobial
Resistance Strategy 2013 to 2018,6 which calls for change in the understanding and response to
antimicrobial resistance by the public, the NHS and the government in the UK. Its overarching goal is to
slow the spread of antimicrobial resistance through three strategies: (1) improving the knowledge and
understanding of antimicrobial resistance, (2) conserving and stewarding the effects of existing antibiotics
and (3) stimulating the development of new antibiotics. Conserving and stewarding the effects of
antibiotics can be achieved in five ways: (1) reducing the overall quantity of antibiotics prescribed and
consumed; (2) when antibiotics are needed, promoting the use of narrow-spectrum agents; (3) when
antibiotics are in demand but are ineffective, providing alternatives; (4) reducing the transmission of
antibiotic-resistant bacteria; and (5) vaccinating against antibiotic-resistant bacteria.
Acute otitis media is a common, painful condition of childhood that has an impact on the family because
of disrupted sleep and time off work and school. Primary care consultation and prescription of an antibiotic
have been the mainstay of management; one UK study found that between 80% and 84% of children
presenting to primary care with AOM were prescribed an antibiotic during the years 1995–2011.1,2 This is
despite the available evidence of benefit being restricted to children < 2 years old with bilateral AOM and
those with otorrhoea,7 leading the National Institute for Health and Care Excellence (NICE) to conclude
that these are the only children warranting a same-day full course of antibiotic treatment.8 For other
children, the use of a ‘wait-and-see’ strategy, with or without a delayed prescription for an antibiotic,
has been shown to be safe in terms of treatment failure and in the frequency of complications of AOM
including mastoiditis.9,10
Evidence of the effectiveness for alternatives to antibiotics is urgently needed to reduce the largely
inappropriate reliance on antibiotics and to relieve the most common and distressing symptoms of AOM.
The results of the Children’s Ear Pain Study (CEDAR) are presented in this report, which investigated if
anaesthetic ear drops are effective in reducing the consumption of antibiotics by children with AOM.
Literature review
Three previous trials have assessed the effectiveness of topical analgesia against placebo in relieving pain
due to AOM.11–13 All were included in a Cochrane review (updated in 2011) that concluded that ‘the
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evidence from [these] RCTs is insufficient to know whether ear drops are effective’.14 In any case, those
studies did not assess the impact of topical analgesia on antibiotic prescribing when used as an approach
to the management of an episode of AOM, and so it is unknown whether or not parents will see topical
analgesia as an effective and preferable alternative to antibiotics and, therefore, reduce unnecessary
antibiotic use.
Benzocaine–phenazone otic solution (Auralgan®, currently manufactured by Pfizer Consumer Healthcare)
drops have been used in Australia for > 40 years with little or no evidence of harm. Prior to commencing
this study, as part of the trial risk assessment and because of the theoretical potential for induced
methaemoglobinaemia, we undertook a search of the Australian Therapeutic Goods Administration
Database of Adverse Event Notifications (DAEN) (www.tga.gov.au/database-adverse-event-notifications-daen).
On 2 December 2015, the DAEN was searched for adverse event reports associated with Auralgan between
1 January 1971 and 19 August 2015. A total of 11 cases were reported, all of which appear to be minor
adverse effects (some patients had more than one adverse effect): ear pain (two cases), discomfort (two
cases), pruritus (one case), hyperacusis (one case), hearing impaired (one case), eye pain (one case), tinnitus
(one case), burning sensation (two cases), ear canal erythema (one case), accidental exposure and overdose
by child (one case), deafness (two cases), depressed mood (one case). This suggests a low risk of adverse
reactions to Auralgan ear drops. There is a further potential for adverse effects arising from reduced antibiotic
prescribing to children with AOM. However, previous observational data suggest that the frequency of such
adverse effects is likely to be extremely low.1 Moreover, in a survey of Australian pharmacies undertaken as
part of preparation for the trial, it was established that these drops are widely available over the counter
and sometimes used to avoid the need for a GP consultation (Harriet Downing, University of Bristol, 2015;
unpublished survey data).
Study aim
The aim of the CEDAR trial is to investigate the clinical effectiveness and cost-effectiveness of benzocaine
plus phenazone (active) ear drops compared with usual care (no drops) for reducing antibiotic consumption
in children aged between 12 months and 10 years presenting to primary care with AOM.
Specific research questions
Following a presentation to primary care with AOM and compared with usual care:
1. Do active drops lead to a lower proportion of children consuming antibiotics in the first 8 days?
2. Do active drops lead to reduced oral analgesic consumption in the first 8 days?
3. Do active drops provide superior pain relief in the first 24–36 hours?
4. Do active drops provide superior pain relief in the first 24 hours?
5. Do active drops alter the number of days before starting antibiotics in the first 7 days?
6. Do active drops reduce the overall symptom burden, including episodes of crying or distress, disturbed
sleep, interference with normal activity, appetite and fever, in the first 7 days?
7. Do active drops alter overall illness duration?
8. What are the net incremental costs to the NHS and society in the short (7 days) and medium
(3 months) term?
9. Are the net incremental costs of active ear drops justified by improved pain relief, symptom burden,
antibiotic use or quality of life?
Further objectives were to use qualitative methods to investigate parents’ and clinicians’ views and experiences
of AOM in children in the CEDAR trial and to investigate the representativeness of the CEDAR trial sample by
describing the presentation, management and outcome of children with AOM in primary care.
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Chapter 2 Methods
Study design
The CEDAR trial was a multicentre randomised controlled trial (RCT) and the participating children were
randomly allocated between three study groups: active treatment (benzocaine-based ear drops), placebo
treatment (drops without the ‘active’ ingredient) and no drops (current standard care). Parents who did
not want their children to take part in the trial but were willing to complete the study diary were offered
enrolment in an observational cohort study (Figure 1).
Recruitment sites and site training
General practitioners at primary care research network practices in Bristol, Cardiff and Southampton were
invited to take part in the study.
Training was delivered to each clinician who was involved in the trial. The training provided an outline of all
trial recruitment and baseline data collection procedures, including how to train parents in administering the
ear drops (for parents of children allocated to one of the treatment groups) and completing the Symptom
and Recovery Questionnaire. A clinician training log was maintained at sites and within the Trial Master File
reflecting the staff who had been trained. Clinicians at all participating primary care sites were also offered
ongoing support, recruitment advice and refresher training on request by the study team.
Participants and recruitment
Eligibility
Children were eligible if they met all of the following criteria:
1. Aged ≥ 12 months and < 10 years.
2. Presenting within 1 week of suspected AOM onset (other preceding respiratory tract infection
symptoms may be longer).
3. Parent/legal guardian available to give consent.
4. Parent-reported ear pain in 24 hours pre enrolment (or parent-suspected ear pain if child is too young
to report pain).
5. Clinician diagnosis of AOM.
6. Child is immunocompetent.
Active ear
drops plus
usual care
Usual care Usual care
OCS
Ear drops
No ear drops
Placebo ear
drops plus
usual care
RCT
FIGURE 1 The CEDAR trial three-group randomised study with observational cohort study. OCS, observational
cohort study.
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7. Clinician willing to use a NICE-recommended ‘no’ oral antibiotic prescribing strategy or a ‘delayed’
oral antibiotic prescribing strategy (as per NICE guidelines15) for the AOM and other elements of the
underlying acute respiratory tract infection. NICE recommends a ‘no’ or ‘delayed’ antibiotic prescribing
strategy for most immune-competent children with AOM.
8. Parent able to give ear drops.
9. Parent willing in principle to use ear drops before oral antibiotics and to wait before giving delayed
antibiotics as per NICE guidelines.
10. Parent able to report the child’s ear pain.
11. Parent able and willing to complete daily Symptom and Recovery Questionnaire and receive regular
follow-up telephone calls in the English language, on the first day of the trial and every 2 or 3 days for
up to 7 more days (or until child has been free of ear pain without medicines for 2 days running).
Children were not recruited if they matched any of the following exclusion criteria:
1. Child requires immediate hospitalisation.
2. Child requires same-day oral antibiotic treatment for AOM or other elements of the underlying acute
respiratory tract infection (these children assessed for observational study eligibility). NICE recommends
same-day antibiotic treatment for:
i. child < 2 years with bilateral AOM
ii. otorrhoea (discharge from the ear)
iii. child who is systemically very unwell or showing signs of respiratory distress (e.g. tachypnoea,
hypoxia or recession)
iv. child who has symptoms and signs suggestive of serious illness and/or complications
(particularly mastoiditis)
v. child who is at a high risk of serious complications because of pre-existing comorbidity. NICE
guidelines recommend that the following children receive same-day antibiotics:
– child who has significant heart, lung, renal, liver or neuromuscular disease (defined for the
purposes of this study as requiring ongoing inpatient or outpatient care from specialist teams)
– child who has immunosuppression (defined for the purposes of this study as a formal diagnosis
of immunosuppression)
– child who has cystic fibrosis
– child who was born prematurely (defined for the purposes of this study as born < 34 weeks
and presenting within the first year of life)
– note: children with other conditions who are at higher risk of AOM (e.g. Down’s syndrome,
cleft palate) may take part if the responsible clinician feels that they meet the inclusion
criteria above.
vi. Child who requires same-day oral antibiotics for another (non-AOM) infection or topical antibiotic
ear drops.
vii. Child who is currently receiving (or has received in the past 7 days) oral or ear drop (to the AOM ear)
antibiotic treatment.
viii. Suspected or confirmed perforation (owing to theoretical and unconfirmed risk of ototoxicity from
active drops) or grommets still in situ.
ix. Known sensitivity to trial medicine (Auralgan) or to its ingredients (benzocaine, phenazone,
glycerine, hydroxyquinoline sulphate) or similar substances (e.g. other ester-type anaesthetics,
such as procaine, tetracaine).
x. Known porphyria or haemoglobinopathy or glucose-6-phosphate dehydrogenase (G6PD) deficiency
or methaemoglobinaemia.
xi. Known family history of G6PD deficiency (noting that G6PD deficiency is more common in African,
Asian and Mediterranean populations).
xii. Current use of sulphonamides, antimalarials, hyaluronidase or St John’s wort.
METHODS
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xiii. Child who needs to continue taking other medicinal products containing benzocaine.
xiv. Child who has proven alternative source(s) of pain other than, and more severe than, the ear
symptoms with which they are presenting.
xv. Otoscopic appearances (as ascertained by clinician, when possible) consistent with observed fever
(i.e. likely non-specific viral illness only, for example with just a slightly perfused or pink drum only).
xvi. Child who has normal ear on examination.
xvii. Child who has otitis externa, or other disorder of the outer ear or tympanic membrane for which
the CEDAR trial ear drops should not be prescribed, in the AOM ear.
xviii. Child who has a hearing aid and parent feels hearing aid should remain in place in the AOM ear.
xix. Symptoms (i.e. hearing loss and longer duration of illness) more suggestive of a diagnosis of otitis
media with effusion (glue ear).
xx. Child who has previously taken part in the CEDAR trial.
xxi. Child who has taken part in any research involving medicines within the last 90 days, or any other
AOM-related research within the last 30 days.
Changes to the eligibility criteria
The team investigated methaemoglobinaemia and its association with benzocaine consumption in children.
Although the potential risk was deemed very small, a decision was made to exclude children under the age
of 12 months, rather than 6 months as previously planned.
Interventions
The investigational medicinal product (IMP) for this trial was a benzocaine and phenazone otic solution. This is an
oil-based, combined local anaesthetic (benzocaine) and analgesic (phenazone) ear drop. One millilitre contains
14mg (1.4%) of benzocaine and 54mg (5.4%) of phenazone suspended in a glycerine-based liquid along with
a preservative (hydroxyquinolone sulphate). Despite an absence of published evidence of effectiveness, it is
available as a pharmacy medicine in Australia and New Zealand, and has been marketed since 1947 under
Auralgan and other brand names. For this trial we intended to test Auralgan sold in 15-ml bottles.
The placebo was glycerine, with packaging as close in appearance as possible to that used for the
active drops.
Outcomes
Primary outcome
Proportion of children who consumed antibiotics by day 8: parents of the children recruited into the
CEDAR trial were asked to complete an 8-day Symptom and Recovery Questionnaire which asked, on each
day, whether or not they had given the child antibiotics. Completion of all eight questions was required to
create an overall consumed/did not consume binary variable.
Secondary outcomes
Ear pain score on day 2
The 8-day Symptom and Recovery Questionnaire also asked the parent to rate their child’s ear pain on a
scale of 0–10 (Figure 2). Although active drops should have an almost immediate effect, the evening of
day 2 was chosen as the time at which the drops had enough time to ease ear pain if they were going to.
Active and placebo drops were compared to see whether or not the active ingredient provided relief over and
above the soothing effects of the oily liquid in which they are contained. Placebo drops were also compared
with usual care to test whether or not the oily liquid itself was more effective than nothing at all. The key
secondary outcome tested the difference in ear pain scores between active and placebo drops, whereas an
additional secondary outcome tested difference in ear pain between placebo and usual-care groups.
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Ear pain score on day 1
Another objective was to see whether or not the drops had an immediate effect on pain; therefore,
parents were asked to score their child’s ear pain 1 hour after giving the first dose of ear drops. Active and
placebo drops were compared to see whether or not the active ingredient provided relief over and above
the soothing effects of the oily liquid in which they are contained. Pain scores were on a scale of 0–10.
This was then compared between active and placebo groups.
Analgesic consumption
On each day of the symptom diary, parents were asked whether or not they had given their child any
analgesics (e.g. ibuprofen or paracetamol). The number of doses was also recorded. A binary variable was
created to identify children who had received analgesics on any of the first 8 days versus children who had
not received any oral analgesics during any of the first 8 days; this measure was not derived for children
with any missing oral analgesic data during the first 8 days. This measure was then compared between
active and placebo groups.
Number of days before taking antibiotics
The number of days before taking antibiotics was obtained from the child’s symptom questionnaire.
This was then compared between active and placebo groups, and between active and usual-care groups.
Mean overall symptom severity on days 1–4
Parents were asked to complete questions concerning other symptoms, such as episodes of crying, disturbed
sleep and fever in their symptom diaries. Symptoms were rated on a scale of 0 (no problem) to 6 (extremely
bad). All symptom scores were combined for each patient per day before calculating the area under the
curve for days 1 to 8. This was then compared between active and placebo groups, and between active and
usual-care groups.
Overall illness duration
The number of days until the parent rated score was 0 for 2 consecutive days was calculated for all children.
This was then compared between active and placebo groups, and between active and usual-care groups.
Adverse events
Details of serious adverse events were collected, and the trial team notified immediately, using adverse
event forms. Parents were also asked on the last day of their questionnaire whether their child had
experienced any new or worsening symptoms during the trial.
FIGURE 2 Parent-completed assessment of pain.
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Patient satisfaction
Parents were asked about their satisfaction with, and opinion of, treatment allocation and future intention
to use drops (with/without prior GP consultation if drops were to become available over the counter)
8 days post randomisation.
NHS and societal costs
The net incremental costs to the NHS and society of using active ear drops compared with no drops (usual
care) in the short (8 days) and medium term (3 months). NHS resource use (e.g. antibiotic or analgesic use,
GP visits) and societal costs (school/nursery absences, parent lost productivity and other family expenses)
were reported by parents in the 8-day questionnaire. Medium-term NHS resource use was collated from a
review of the child’s GP records.
Child’s quality of life
Preference-based quality of child life was measured (baseline, 24–36 hours, 8 days and 3 months post
randomisation) using the CHU-9D.16 The CHU-9D is not designed for, or validated for, preschool children;
therefore, this measure was used only in children aged ≥ 5 years. The OMQ-1417 was given at baseline and
3 months post randomisation for children aged ≥ 2 years (clinical report form and postal/online questionnaire
at 3 months).
Sample size
Previous studies have suggested that 80–90% of children presenting to UK GPs with AOM receive a
prescription for an antibiotic.18,19 It has also been argued that a 20% change in consumption could have
important effects on antimicrobial resistance.3 The number of children needed in each group (active ear
drops and usual care) to demonstrate a true 20% fall in antibiotic consumption, from 80–90% in the
control group to 60–70% in the active ear drop group, with 90% power and two-sided significance level
of 0.05, ranged from 92 to 119. Using the more conservative estimate of 119 children, and making
provision for 20% attrition, this gave a target sample size of 149 children per group.
Our key secondary outcome was pain on day 2, measured using a validated 0–10 numerical rating scale.
Based on the findings of a previous study using this measure,20 and the opinions of our patient and public
involvement group, it was felt that a reduction in pain of 1 point was a clinically important difference.
With 90% power and α = 0.05, we can detect a true mean difference of 1 point [standard deviation (SD)
2.5 points] in pain score between the active and placebo ear drop groups, detected with 90% of power
at the two-sided significance level of 0.05, with 133 children per group. Accommodating 20% attrition,
and assuming equal numbers in the three groups, we needed 167 children per group (more than for the
primary outcome) and 501 children in total.
Random allocation
Each pack contained two bottles of active medicine, two bottles of placebo medicine or no bottles but a
non-medicinal item of similar weight. Randomisation was stratified by centre in blocks of 30 packs, each block
having the packs arranged in a random and consecutively numbered sequence. The Bristol Randomised Trials
Collaboration provided the pharmaceutical supplier with a set of patient IDs, which were allocated to a pack
according to the sequence for the current block for a centre. The supplier provided the pharmacy with
medicine packs that had each been prelabelled with the patient ID and medicine pack ID numbers.
Patients were enrolled by their GP or research nurse who, at the stage of enrolment, was unaware of the
contents of the next treatment pack in the sequence (allocation concealment). When the informed consent
process was completed and signed, the trial pack was opened and allocation to drops (active or placebo)
or not was confirmed.
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Blinding
Although parents were aware if their child had been allocated to the usual-care group, if they received
drops they were not aware if they had received active or placebo drops. An unblinded comparison of
parents provided with ear drops and those allocated to usual care was the appropriate approach to
establish if the provision of ear drops would reduce antibiotic consumption in children with ear pain due
to AOM. All parents, researchers and clinicians were blinded to the treatment allocation between active
and inactive drops as far as possible. The statistician had unblinded access to the data in February 2017,
to report to the Data Monitoring Committee, when approximately 50 patients had been recruited.
Statistical methods
The main statistical analyses were prespecified in a statistical analysis plan. The final version of the statistical
analysis plan was signed off on 19 September 2017. A confidential interim analysis was completed in
February 2017 for the Data Monitoring Committee. Final data analysis started in October 2017 and finished
in January 2018. Stata® 14.2 (StataCorp LP, College Station, TX, USA) was used for all statistical analyses.
Statistical primary analysis
All parents of recruited children were asked to complete an 8-day symptom diary that asked, on each day,
‘Did your child take any antibiotics by mouth today?’. The primary analysis was conducted using the modified
intention-to-treat (ITT) approach, including only children with full 8-day data for this question. We used
logistic regression to compare children who had taken antibiotics on any of the 8 days with those who had
taken no antibiotics during the first 8 days.
H0: the proportion of children consuming antibiotics is the same in both groups.
H1: the proportion of children consuming antibiotics is different between the groups.
The primary hypothesis was whether or not active drops reduced the proportion of children consuming
antibiotics compared with usual care (no drops).
Statistical secondary analyses
As for the primary analysis, secondary outcome measures were compared between the study groups using
an appropriate regression model. When data were skewed, the square root transformation was used to
obtain a difference in means. Descriptive statistics were presented for adverse events and patient
satisfaction.
Sensitivity analyses
We prespecified a per-protocol analysis, as a sensitivity analysis, including participants in the full analysis
set who were deemed to have no major protocol violations that could interfere with the objectives of
the study. Compliance per day was measured only for days when the pain score was ≥ 1. Any volume of
liquid used on that day was considered compliant. Therefore, if there was patient-reported pain for 5 out
of 8 days, and drops were used for all five of the days with pain, then we classed this as 100% compliance.
We carried out a per-protocol analysis for which we removed any patients from the active group who were
considered non-compliant. This was prespecified as those taking their trial medication on < 50% of the days
that they reported pain.
In a further sensitivity analysis, those who were lost to follow-up in the active drops group were assumed
to have taken antibiotics and those in the usual-care group were assumed not to have done so.
As a post hoc sensitivity analysis we removed patients who were found to be ineligible after having been
recruited to the study and allocated to a group.
METHODS
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Subgroup analyses
The following subgroups of children were prespecified for investigation of any treatment effect differences
on the primary outcome measure. A treatment subgroup interaction term was added to the appropriate
regression model:
l prior duration of illness (≤ 72 hours vs. > 72 hours)
l visibility of the ear drum (yes or no)
l extent of AOM (unilateral or bilateral)
l whether or not they had been given a delayed antibiotic script.
Recurrence of AOM was listed in the analysis plan in error (as it is a measure of outcome); therefore, this
subgroup analysis did not go ahead.
Exploratory analyses
Exploratory analyses were used to help us contextualise our main findings, by investigating the effects of
antibiotics and analgesics on pain.
Health economic methods
The prespecified economic analysis consisted of a cost-effectiveness analysis and cost–consequence
study. As antimicrobial resistance is such an important concern,21 our primary economic analysis was a
cost-effectiveness analysis with antibiotic use as a proxy for this outcome. The economic case for or against
the active drops is most likely to hinge on externalities, that is antibiotic use and resistance, in the
population, rather than purely on within trial estimates of costs and quality of life. The cost–consequence
study (including quality of life) was a secondary economic analysis.
The primary comparison was the NHS and societal cost per antibiotic consumption avoided during the
acute episode between those children receiving active ear drops and those receiving usual care. The active
treatment (Auralgan) is currently not in the British National Formulary (BNF)22 or available in UK pharmacies
and, therefore, there is no national unit cost available. Auralgan is available to purchase over the counter in
Australian pharmacies. The median retail cost for a 15-ml bottle in December 2017 at 10 online Australian
pharmacies was AU$10.99, equivalent to approximately £5.20 when converted using 2016 Organisation for
Economic Co-operation and Development purchasing power parity statistics23 or £10.40 retail cost for the
two 15-ml bottles given to each participant in the active drops group of the trial. We assumed that, if used
in routine UK clinical practice, Auralgan would be prescribed by a GP and, therefore, the cost would be
borne by the NHS rather than by the family. For many medicines, the NHS drug tariff paid to pharmacies is
much lower than the retail cost. For example, for 120 mg/5 ml of oral suspension paracetamol the drug
tariff cost is approximately one-third of the retail cost. Therefore, in our primary analysis we assumed that
the cost to the NHS of two 15-ml bottles of Auralgan would be £3.54 and we conducted a sensitivity
analysis assuming that the NHS would pay the retail cost of £10.40.
The incremental NHS treatment costs during the first 8 days after randomisation were ascertained from
the symptom and recovery questionnaire and valued using national unit costs22,24 using 2016/17 values,
when available. Parents recorded whether or not their child received an antibiotic on each day that
symptoms persisted. We assumed that the antibiotic prescribed was 250 mg of amoxicillin, three times a
day (age 1–4 years) or 500 mg three times a day (age ≥ 5 years) for 7 days. Using the NHS drug tariff
price,25 this equates to a cost of £1.17 (age 1–4 years) or £2.34 (≥ age 5 years) per antibiotic prescription.
Parents also recorded daily use of ibuprofen or paracetamol during the first 8 days. When use was
reported, we assumed this was prescribed (i.e. it was a cost borne by the NHS) and that age-appropriate
doses were given. For example, based on national drug tariff prices,25 the cost of a 2-year-old child taking
100 mg/5 ml of ibuprofen three times a day for a total of 20 doses is £1.28.
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For Auralgan and antibiotics, we assumed that the whole cost would be incurred no matter how frequently
parents administered the medicine (i.e. the remaining medication would be disposed of after the acute
episode rather than reused during later episodes). For paracetamol and ibuprofen, we assumed that the cost
of the medication would be proportional to the number of times it was administered (i.e. the remaining
medication would be stored and reused during later episodes).
On the eighth day after randomisation, parents were asked to report any further consultations with their
GP, the NHS 111 telephone service or hospital ambulatory care relating to their child’s ear symptoms.
Parent productivity costs were measured on the 8-day questionnaire and valued using average earnings.
Bootstrapping was used to calculate confidence intervals (CIs) around the point estimate of the incremental
cost-effectiveness ratio and cost-effectiveness acceptability curves.
In the secondary economic analysis, we prespecified a cost–consequence study tabulating 3-month
treatment costs, including data from the 3-month GP note review, alongside other important outcomes
including 24- to 36-hour ear pain relief, overall symptom burden, acute illness duration and CHU-9D utility
scores. At the request of the funder, the GP note review was not conducted; therefore, we did not estimate
3-month treatment costs and instead present only CHU-9D utility scores at 3 months.
Qualitative methods
To examine the views and experiences of AOM and its treatment, qualitative interviews were conducted
with parents and clinicians involved in the care of trial participants. The interview topic guide included the
perceived effectiveness and acceptability of treatment and exploration of any barriers to treatment uptake
outside the trial.
Sampling
All parents agreeing to participate in the trial were asked, at the time of consent, if they were willing to be
contacted about taking part in a telephone interview. From willing participants, a purposive sample was to
be drawn in relation to (1) trial site (Bristol, Southampton, Cardiff), (2) trial group (active/placebo or usual
care) and (3) sociodemographic factors including child’s age, ethnicity and socioeconomic status (with
participants being selected from areas of high and low social economic deprivation, based on an Index of
Multiple Deprivation score).26 Health-care professionals (GP’s and nurse practitioners) involved in the trial
were to be purposively sampled in relation to (1) trial site and (2) length of time since qualification. Sample
sizes would be determined by the need to achieve data saturation, such that no new themes emerged by
the end of data collection.27 Interviews were to be analysed in batches and sampling to continue until no
new themes emerged.
Interview conduct
In-depth telephone interviews were conducted with parents 14 days afer randomisation. Lines of questioning
within interviews focused on views and experiences of (1) the disease, (2) its diagnosis, (3) treatment and
recovery, (4) information and support needs and (5) views and experiences of participation within the trial.
Interviews also explored the potential implications of making the CEDAR drops available over the counter,
following which the costs will shift from the NHS to the individual. Health-care professionals were to be
interviewed to explore their views and experiences of the trial, information and support needs and their
attitudes to the future implementation of treatments.
All interviews were conducted by telephone. At interview, participants were asked to give verbal consent,
following which a flexible interview topic guide was used to ensure that primary issues were covered during
all interviews, but without dictating data collection. This allowed participants to introduce unanticipated
issues. The interviewer (CC) used open-ended questioning techniques to elicit participants’ experiences and
views of key events and participants were asked to provide examples. Interviews were recorded using a
METHODS
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digital voice recorder, transcribed using a professional transcription service and anonymised to protect
confidentiality. Parents who took part in interviews received a £10 high street voucher.
Qualitative data analysis
Interview transcripts were checked for accuracy and then imported into NVivo 11 (QSR International,
Warrington, UK) qualitative analysis software to aid management and indexing of data. Analysis began after
the first interview and was ongoing and iterative. Earlier data were to inform further data collection; for
instance, analytical insights from data gathered in earlier interviews would help identify any changes that
needed to be made to the topic guide during later interviews. Thematic analysis28 utilising a data-driven
inductive approach29 was used to identify and analyse patterns and themes of salience to participants and
across the data set using constant comparison techniques.30,31 First transcripts were read several times, to
gain familiarisation with the data and initial ideas. Transcripts were then examined line by line, with inductive
codes being assigned to data segments that provided insight to participants’ views and understandings.
An initial coding frame was developed and newer data were compared with previous data and then with
the properties of emerging categories that contain the main themes. The process of constant comparison
allowed the generation of new themes, reclassification of themes and incorporation of themes within other
themes, with the coding frame being modified as analysis developed. A subset of transcripts was to be
independently double-coded by other members of the research team and compared, and discrepancies
discussed and resolved, to achieve a coding consensus and to maximise rigour.
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Chapter 3 Results
Study progress
Study recruitment had been planned to take place between June 2015 and June 2017. Owing to a delay
in the supply of a suitable placebo, recruitment began in October 2016 across 27 GP practices with a
two-group internal pilot phase. Children were randomly allocated to the active treatment group or the
usual-care group. The protocol change necessary for the two-group trial (protocol version 1.4) received
approval from the ethics committee in August 2016 (NHS HRA reference 15/SC/0376). When the placebo
became available in March 2017, the three-group study began recruiting across 35 GP practices. Although
the two- and three-group designs ran concurrently for 3 months, the two studies did not run at the same
time within any given practice. Owing to the late start of the three-group trial, the observational cohort
for parents who did not want their children to take part in that trial but were willing to complete the study
diary (see Figure 1) was not initiated. Recruitment to the trial closed as planned in June 2017, with a
recruitment period of 9 months having been achieved rather than the planned 24 months.
In April 2017, a Data Monitoring Committee meeting was held that highlighted that antibiotic prescribing
rates were much lower than assumed in all study groups combined and, consequently, that the sample
size target would not provide 90% statistical power. This may in part have been due to children requiring
immediate antibiotics, and so ineligible for the trial, accounting for a bigger than assumed proportion
of those prescribed antibiotics in the studies used to inform the sample size calculation. Following this
finding, the Trial Management Group, along with the Trial Steering Committee, jointly agreed that the
data collected should serve as internal pilot data (i.e. the data would be included in the primary analysis)
and an application made to extend the study to allow further recruitment with a revised exclusion criterion
relating to antibiotic prescribing.
In Autumn 2017, this application to extend the study was declined by the funders, and the study was
required to close by the 31 December 2017, several months earlier than originally planned. Owing to this,
no 3-month reviews of primary care records were conducted and so planned analyses relying on those
reviews were not possible. The following presentation of results has adhered as closely as possible to the
prespecified statistical analysis plan, including an amendment written as part of the study close-down plan,
which adapts the original plan to data available from the internal pilot and full three-group stages.
Recruitment and completion of follow-up assessments
Seventy-four children were recruited during the two-group internal pilot, which ran from October 2016 to
the end of April 2017, in 27 GP practices situated in all three centres. Thirty-two children were recruited
to the three-group study, which ran from March 2017 to June 2017, in 35 GP practices in Bristol and
Southampton. All 106 patients were recruited by 17 GPs, 18 nurses and 3 other health-care professionals,
with each recruiting between 1 and 19 children. Our interim recruitment target at the end of June was
150 participants. After initially recruiting to target, recruitment fell short of the June target in part because
of the time taken to switch practices from the two-group to the three-group trial and in part because of
the limited supply of treatment packs (see Appendix 1 for the chart used to monitor recruitment).
Figure 3 shows the stages of the trial and the different levels of dropout that led to the final analysis
sample. Overall, five patients randomised into the trial were found to be ineligible post randomisation.
For three of these patients (two active two-group patients and one usual-care two-group patient), this was
discovered shortly after randomisation and the patients were advised to return the drops and not complete
the diary. For the other two of these patients, this was noticed only after follow-up had been completed.
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Randomised to
active
(n = 38)
Two-arme
(n = 74)
No follow-up data
(n = 4)
• Withdrew, n = 1
• Found to be ineligible
   post randomisation, n = 2
• Lost to follow-up, n = 1
Partial follow-up
(n = 5)
Analysis
Active drops
Primary (n = 29)
Secondary (n = 32)
Randomised to
no drops
(n = 36)
No follow-up data
(n = 5)
• Withdrew, n = 2
• Lost to follow-up, n = 3
• Lost to follow-up, n = 1
Partial follow-up
(n = 1)
Analysis
No dropsf
Primary (n = 30)
Secondary (n = 30)
Randomised to
active
(n = 12)
No follow-up data
(n = 2)
• Found to be ineligible
   post randomisation, n = 1
• Lost to follow-up, n = 1
Analysis
Active drops
Primary (n = 10)
Secondary (n = 10)
Randomised to
placebo
(n = 10)
No follow-up data
(n = 3)
• Lost to follow-up, n = 3
Analysis
Placebo drops
Primary (n = 7)
Secondary (n = 7)
Randomised to
no drops
(n = 10)
No follow-up data
(n = 1)
• Lost to follow-up, n = 1
• Lost to follow-up, n = 1
Partial follow-up
(n = 1)
Analysis
No dropsg
Primary (n = 8)
Secondary (n = 9)
Three-arme
(n = 32)
Recruited
(n = 106)
Consented to participate
(n = 120)
Invited children
(n = 130)
Assessed for eligibility
(n = 190)
Not invited to participate
(n = 60)
Declined participation
(n = 10)
Later found to be ineligible
(n = 10)
Eligible but not recruited
(n = 4)
• Other reason,d n = 4
• < 2 years and has bilateral AOM, n = 3
• Child has otorrhoea (discharge from the ear), n = 2
• Other reason,c n = 5
• Parent did not have time for recruitment, n = 5
• Parent did not want to use eardrops, n = 2
• Other reason,b n = 3
• Clinician did not have time for recruitment in the
   consultation, n = 14
• Child has otorrhoea, n = 7
• Child was < 2 years or > 10 years, n = 6
• Same day oral or topical antibiotics required, n = 4
• Parent or clinician wanted an immediate antibiotic,
   n = 4
• Child too unwell (clinician’s view), n = 3
• No medicine packs available, n = 4
• Parent not in attendance, n = 3
• > 7 days of ear pain, n = 2
• Clinician not available for recruitment at time that
   child presents, n = 2
• Clinician could not get a clear enough view of the
   ear drum, n = 2
• Risk of complications owing to pre-existing
   comorbidities, n = 2
• Other reason,a n = 7
• Withdrew, n = 2
• Lost to follow-up, n = 3
FIGURE 3 The CEDAR trial CONSORT (Consolidated Standards of Reporting Trials) flow chart. a, Been using
dexamethasone/neomycin sulphate/acetic acid spray (Otomize®; Teva UK Ltd.), temporary resident so clinician decided
not to recruit, previously taken part in the CEDAR trial, grommets, history of bloody discharge, dental issue causing ear
pain, patient seen at branch surgery and unable to come to main surgery for appointment; b, child not happy about
taking part, parent did not want to risk getting placebo, parent did not want child to participate; c, child too unwell
(clinician’s view), risk of complications due to pre-existing comorbidities, right ear otitis externa, child too old, no
reason stated; d, child too unwell (clinician’s view), child not happy about taking part, parent did not have time for
recruitment, no reason listed; e, recruitment to the two-group pilot ran from October 2016 to the end of April 2017
(in 27 sites) while recruitment to the three-group pilot ran fromMarch 2017 to June 2017 (in 35 sites); 12 sites recruiting
to the three-group pilot were previously involved in the two-group pilot. Although the two-group and three-group trials
ran concurrently between March 2017 and June 2017, the two trials did not run at the same time within a given site;
f, one patient who completed follow-up was later found to be ineligible (bilateral AOM and < 2 years of age); and
g, one patient who completed follow-up was later found to be ineligible (otorrhoea in right ear).
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Given that our analysis was on an ITT basis, these patients were included in all analyses but excluded in a
sensitivity analysis.32 Further detail of the availability of data on the two key outcomes of antibiotic use over
eight days and pain reported is given in Table 1.
Baseline data
A total of 106 patients were randomised to the CEDAR two- and three-group studies and baseline
characteristics are shown in Tables 2–5, respectively. The team prespecified in the analysis plan that any
baseline characteristics that differed by at least 10%/0.5 SDs would be adjusted for in a sensitivity analysis.
However, as the study recruited only one-fifth of the target sample size, the criterion was increased to
20%/0.75 SDs to counteract the increased chance of finding an imbalance.
In the two-group study, the only measure to have a difference exceeding the prespecified criterion of 20%
or 0.75 SDs was receipt of a delayed prescription for an antibiotic (see Table 3). Those prescriptions should
have been issued, and recorded, prior to randomisation and so it should not be the case that allocation to
study group influenced antibiotic prescription, although we are unable to confirm this for sure.
Prior to analysis, the criterion for imbalance for the three-group study was increased to 30%/1 SD to
counteract the increased chance of finding an imbalance given the small sample size. Variables that
exceeded this criterion were sex, accompanying adult’s age and employment status, living in an area of
deprivation, breastfeeding status at 3 months (see Table 4), episodes of distress/crying and disturbed sleep
(see Table 5).
TABLE 1 Further details on data available for antibiotic consumption and pain outcome measures
Outcome measure
Treatment arm, n (%)
p-valueActive drops Placebo drops Usual care
Two-group study
Number randomised 38 36 –
Found to be ineligible 1 (3) 1 (3) 0.74
Withdrew from study 2 (5) 2 (6) 0.67
Lost to follow-up 6 (16) 5 (14) 0.54
8 days of antibiotic data 29 (76) 30 (83) 0.32
Pain data on days 1 and 2 32 (84) 30 (83) 0.58
Three-group study
Number randomised 12 10 10 –
Found to be ineligible 1 (8) 0 0 –
Withdrew from study 0 0 0 –
Lost to follow-up 1 (8) 3 (30) 1 (10) 0.48
8 days of antibiotic data 10 (83) 7 (70) 8 (80) 0.87
Pain data on days 1 and 2 10 (83) 7 (70) 9 (90) 0.63
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TABLE 2 Baseline characteristics by allocated group, two-group study
Characteristic
Treatment arm
Active drops (N= 38) Usual care (N= 36)
N Mean (SD) or n (%) N Mean (SD) or n (%)
Centre
Bristol 38 23 (61%) 36 23 (64%)
Cardiff 38 5 (13%) 36 4 (11%)
Southampton 38 10 (26%) 36 9 (25%)
Child’s demographics
Sex: male 38 18 (47%) 36 16 (44%)
Age (years) 38 4.6 (2.5) 36 4.6 (2.5)
Aged ≥ 5 years 38 17 (45%) 36 14 (39%)
White ethnicity 34 33 (97%) 31 31 (100%)
Living in an area of deprivationa 37 3 (8%) 35 3 (9%)
Exposure to potential risk factors
Smokers in household 34 2 (6%) 31 1 (3%)
Additional children in household 34 22 (65%) 31 21 (68%)
Breastfed at 3 months 34 14 (41%) 31 9 (29%)
Does the child wear a hearing aid 34 0 (0%) 31 0 (0%)
Flu vaccination in last 12 months 34 15 (44%) 31 16 (52%)
Accompanying adult demographics
Mother attended with child 29 26 (90%) 28 25 (89%)
Accompanying adult’s age (years) 29 35.0 (6.0) 28 36.4 (6.7)
Accompanying adult employed/full time education/retired 34 25 (74%) 31 26 (84%)
Accompanying adult a university graduate 29 11 (34%) 28 11 (39%)
a Index of Multiple Deprivation26 based on the children’s home postcode at birth, categorised as those living in the top
20% of deprived areas in the UK (England’s 2015 rank and Wales’ 2014 rank).
TABLE 3 Clinical characteristics at presentation by allocated group, two-group study
Characteristic
Treatment arm
Active drops (N= 38) Usual care (N= 36)
N Mean (SD) or n (%) N Mean (SD) or n (%)
Ear pain/medication
Child ear pain score (1–10)a 14 6.0 (2.6) 15 6.1 (3.1)
Parent ear pain score (1–10) 38 6.9 (1.5) 36 6.3 (1.7)
Number of days in pain 38 2.7 (2.0) 36 2.5 (1.4)
Received painkillers todayb 37 32 (86%) 34 25 (74%)
Symptoms (scale 0–6)
Episodes of distress/crying 37 3.8 (1.5) 34 3.3 (1.3)
Disturbed sleep 37 4.1 (1.6) 34 3.7 (1.6)
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TABLE 3 Clinical characteristics at presentation by allocated group, two-group study (continued )
Characteristic
Treatment arm
Active drops (N= 38) Usual care (N= 36)
N Mean (SD) or n (%) N Mean (SD) or n (%)
Interference with normal activities 37 3.1 (1.5) 34 2.7 (1.5)
Eating/drinking less than normal 37 2.7 (1.7) 34 2.2 (1.6)
Fever 37 1.9 (1.7) 34 2.7 (1.7)
Hearing problems 37 1.2 (1.4) 34 1.4 (1.8)
Cough 37 2.5 (1.8) 34 1.8 (1.7)
Blocked/runny nose 37 2.3 (1.8) 34 2.1 (1.8)
Vomiting 37 0.5 (1.5) 34 0.4 (1.0)
Clinical examination
AOM in both ears/bilateral 38 8 (22%) 36 5 (14%)
General health of child (0–10)c 38 3.6 (1.9) 36 3.3 (1.8)
Temperature 38 37.0 (0.6) 36 36.9 (0.7)
Given a delayed antibiotic 38 4 (11%) 36 11 (31%)
a Answered by those aged ≥ 5 years.
b ‘Has your child received any painkilling medicine (e.g. paracetamol or ibuprofen) in the last 6 hours before being
checked for trial suitability?’.
c From 0 (not at all unwell) to 10 (extremely unwell).
TABLE 4 Baseline characteristics by allocated group, three-group study
Characteristic
Treatment arm
Active drops Placebo drops Usual care
N
Mean (SD)
or n (%) N
Mean (SD)
or n (%) N
Mean (SD)
or n (%)
Centre
Bristol 8 (67%) 8 (80%) 6 (60%)
Southampton 4 (33%) 2 (20%) 4 (40%)
Child’s demographics
Sex: male 12 11 (92%) 10 3 (30%) 10 5 (50%)
Age (years) 12 4.9 (2.5) 10 5.0 (1.9) 10 4.6 (2.9)
Aged ≥ 5 years 12 7 (58%) 10 5 (50%) 10 7 (70%)
White ethnicity 10 9 (90%) 7 6 (86%) 9 9 (100%)
Living in an area of deprivationa 11 2 (18%) 10 0 (0%) 10 4 (40%)
Exposure to potential risk factors
Smokers in household 10 1 (10%) 7 1 (14%) 9 2 (22%)
Additional children in household 10 8 (80%) 7 4 (57%) 9 7 (78%)
Breastfed at 3 months 10 7 (70%) 7 4 (57%) 9 2 (22%)
Does the child wear a hearing aid? 10 0 (0%) 7 0 (0%) 0 0 (0%)
Flu vaccination in last 12 months 10 4 (40%) 7 4 (57%) 9 4 (44%)
continued
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TABLE 4 Baseline characteristics by allocated group, three-group study (continued )
Characteristic
Treatment arm
Active drops Placebo drops Usual care
N
Mean (SD)
or n (%) N
Mean (SD)
or n (%) N
Mean (SD)
or n (%)
Accompanying adult demographics
Mother attended with child 9 9 (89%) 7 5 (71%) 8 8 (100%)
Accompanying adult’s age (years) 9 38.7 (6.8) 7 37.6 (8.2) 8 31.5 (3.1)
Accompanying adult employed 10 7 (70%) 7 6 (86%) 9 3 (33%)
Accompanying adult a university graduate 9 3 (33%) 7 3 (43%) 8 3 (38%)
a Index of Multiple Deprivation based on the children’s home postcode at birth, categorised as those living in the top 20%
of deprived areas in the UK (England’s 2015 rank and Wales’ 2014 rank).
TABLE 5 Clinical characteristics at presentation by allocated group, three-group study
Characteristic
Treatment arm
Active drops Placebo drops Usual care
N
Mean (SD)
or n (%) N
Mean (SD)
or n (%) N
Mean (SD)
or n (%)
Ear pain/medication
Child ear pain score (1–10)a 7 6.4 (2.3) 4 5.5 (3.0) 4 7.5 (2.5)
Parent ear pain score (1–10) 11 6.3 (1.8) 10 5.3 (1.3) 10 6.2 (2.2)
Number of days in pain 11 1.5 (0.9) 10 2.7 (1.5) 10 2.3 (1.8)
Received painkillers todayb 11 7 (64%) 9 4 (44%) 10 7 (70%)
Symptoms (scale 0–6)
Episodes of distress/crying 11 3.0 (1.7) 9 2.4 (1.3) 10 4.2 (1.7)
Disturbed sleep 11 2.9 (1.5) 9 2.7 (1.3) 10 4.2 (1.3)
Interference with normal activities 11 2.5 (1.8) 9 2.9 (1.5) 10 3.3 (1.3)
Eating/drinking less than normal 11 1.7 (1.6) 9 2.4 (1.8) 10 2.0 (1.7)
Fever 11 1.2 (1.6) 9 2.1 (1.5) 10 2.1 (1.9)
Hearing problems 11 1.4 (1.6) 9 1.0 (1.6) 10 0.7 (1.1)
Cough 11 1.0 (1.0) 9 2.2 (1.7) 10 1.5 (1.6)
Blocked/runny nose 11 1.8 (1.9) 9 1.7 (1.1) 10 2.9 (1.8)
Vomiting 11 0.2 (0.6) 9 0.4 (1.3) 10 0.5 (1.1)
Clinical examination
AOM in both ears/bilateral 11 2 (18%) 10 4 (40%) 10 2 (20%)
General health of child (0–10)c 11 3.9 (1.7) 10 3.3 (1.5) 9 3.1 (1.2)
Temperature 11 37.1 (0.8) 10 37.5 (1.3) 9 37.1 (0.6)
Given a delayed antibiotic 11 3 (27%) 10 1 (10%) 10 3 (30%)
a Answered by those aged ≥ 5.
b ‘Has your child received any painkilling medicine, e.g. paracetamol or ibuprofen, in the last 6 hours before being
checked for trial suitability?’.
c From 0 (not at all unwell) to 10 (extremely unwell).
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Outcomes and estimation
Primary outcome: antibiotic consumption
The primary research hypothesis was to find whether or not active ear drops would reduce antibiotic
consumption compared with usual care. In the two-group study, 30% of patients in the usual-care group
consumed antibiotics by day 8, compared with only 3% in the active drops group (Table 6). The results
from the three-group study, although based on a much smaller sample size, were very similar: 25% in the
usual-care group versus 0% in the active drops group. These two results were combined in a meta-analysis
(with a continuity correction of 0.4444 to allow calculation of an odds ratio in the three-group study).
The combined odds ratio supports the conclusion that, with 95% confidence, the crude odds of taking
antibiotics is between 45% and 98% lower in the active drops group than in the usual care group
(see Table 6). After controlling for the effect of administering a delayed antibiotic script at randomisation,
the CI widens, weakening the evidence against the null hypothesis (see Table 6).
Receipt of a delayed antibiotic script was prespecified as a potential confounding variable in the statistical
analysis plan; Table 7 shows a stratified analysis investigating the impact that the delayed antibiotic script
had on the proportion of children consuming antibiotics. Overall, 47% (9/19) of those children given a
delayed antibiotic script went on to consume an antibiotic, compared with 9% (6/65) of those not given a
delayed antibiotic script. In the two-group study, 70% (7/10) of children given a delayed antibiotic went
on to consume antibiotics if they were in the usual-care group, compared with 0% (0/3) of the children in
the active drops group.
Data from the three-group study were used to investigate whether or not active ear drops would reduce
antibiotic consumption compared with placebo drops. A total of 43% (3/7) of patients in the placebo
drops group consumed antibiotics by day 8, compared with 0% (0/10) in the active drops group. Using a
Fisher’s exact test, there is moderate evidence to suggest that active drops reduce antibiotic consumption
compared with placebo drops (p = 0.051).
TABLE 6 Primary analysis: antibiotic consumption, by group
Group
Treatment arm, n/N (%)
OR (95% CI) p-value OR (95% CI)a p-valueaActive drops Usual care
Two-group 1/29 (3) 9/30 (30) 0.08 (0.01 to 0.71) 0.023 0.12 (0.01 to 1.18) 0.069
Three-group 0/10 (0) 2/8 (25) 0.11 (0.00 to 3.17)b 0.201 0.20 (0.01 to 3.49)b 0.270
Combined 1/39 (3) 11/38 (29) 0.09 (0.02 to 0.55)c 0.009c 0.15 (0.03 to 0.87)d 0.035d
OR, odds ratio.
a Adjusted for delayed antibiotic script, missing for one patient in the three-group trial.
b Continuity correction of 0.4444.
c Pooled estimate using the inverse variance method, I2 = 0.0%.
d Pooled estimate using the inverse variance method, I2 = 29.1%.
TABLE 7 The impact of giving a delayed antibiotic script on consumption of antibiotics, by group
Antibiotic consumption
Group, n/N (%)
Two-group study Three-group study
Active drops Usual care Active drops Placebo drops Usual care
Prescribed delayed antibiotic 0/3 (0) 7/10 (70) 0/3 (0) 0/0 (0) 2/3 (67)
No prescribed delayed antibiotic 1/26 (4) 2/20 (10) 0/7 (0) 3/7 (43) 0/5 (0)
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Key secondary outcome: ear pain on day 2
Parent-reported pain scores at day 2, in the three-group study, are presented in Table 8. There was no
evidence to suggest that pain was reduced in active compared with placebo drops groups. Unadjusted and
adjusted results were in favour of the placebo drops, with pain scores observed to be, on average, 0.96
points higher in the active group. There was evidence to suggest that pain was reduced in the placebo
drops group compared with the usual-care group. Unadjusted and adjusted results were in favour of the
placebo drops with pain scores on average 2.86 points higher in the usual-care group (see Table 8), and
the 95% CI excluded the prespecified 1-point minimum clinically important difference.
We carried out a post hoc secondary analysis comparing ear pain between the active and usual-care
groups. There was evidence (Table 9) to suggest that active ear drops reduced ear pain, which was
strengthened after adjusting for baseline ear pain (at consultation). After adjustment, the combined mean
difference was almost 2 points on the 0- to 6-point scale, with the 95% CI almost excluding the minimum
clinically important difference and close to the effect of the placebo drops reported in Table 8.
Secondary outcome: ear pain on day 1
There was no evidence to suggest that pain was reduced in the active drops group compared with the
placebo drops group on day 1 (Table 10).
TABLE 8 Key secondary analysis: ear pain score on day 2, by group
Treatment arm Ear pain, mean (SD); n
Mean difference
(95% CI) p-value
Mean difference
(95% CI)a p-valuea
Placebo drops 2.14 (1.07); 7 Comparison
Active drops 3.10 (2.23); 10 0.96 (–0.99 to 2.91) 0.312 0.67 (–1.44 to 2.79) 0.506
Usual care 5.00 (1.73); 9 2.86 (1.25 to 4.46) 0.002 2.86 (1.13 to 4.60) 0.003
a Adjusted for the parent reported pain score at consultation.
TABLE 9 Exploratory analysis: ear pain on day 2, by group
Group
Treatment arm, mean (SD); n
Mean difference
(95% CI) p-value
Mean difference
(95% CI)a,b p-valuea,bActive drops Usual care
Two-group 2.81 (2.32); 32 4.43 (2.54); 30 –1.62 (–2.86 to –0.39) 0.011 –2.01 (–3.23 to –0.78) 0.002
Three-group 3.10 (2.23); 10 5.00 (1.73); 9 –1.90 (–3.85 to 0.05) 0.056 –1.93 (–3.92 to 0.05) 0.055
Pooled 2.88 (2.28); 42 4.56 (2.37); 39 –1.70 (–2.74 to –0.66) 0.001 –1.99 (–3.01 to –0.95)b < 0.001b
a Adjusted for the parent-reported pain score at consultation.
b Pooled estimate using the inverse variance method, I2 = 0.0%; p= 0.884.
TABLE 10 Secondary analysis: ear pain on day 1 (approximately 1 hour after administering the drops), by group
Group
Treatment arm, mean (SD); n
Mean difference
(95% CI) p-value
Mean difference
(95% CI)a p-valueaActive drops Usual care
Ear pain 2.70 (1.16); 10 3.42 (1.62); 7 –0.73 (–2.16 to 0.70) 0.295 –0.74 (–2.32 to 0.85) 0.338
a Adjusted for the parent-reported pain score at consultation.
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Combining the two- and three-group study data, Figure 4 shows the average daily pain scores for each of
the three groups. Over the 8 days, lower levels of pain were reported by the active drop and placebo drop
groups than by the no drops group.
Secondary outcome: oral analgesic consumption
Oral analgesic consumption was high, with 88% of children taking paracetamol or ibuprofen during the
first 8 days after consultation. There was no evidence to suggest a difference in oral analgesic consumption
between those taking active and placebo ear drops (Table 11).
During the recruitment process, parents were asked if their child had received any painkilling medicine
prior to the recruitment consultation and 56 out of 79 (71%) participants said that they had. All 56 of
these children subsequently received analgesics during the study. Out of the 23 who did not give their
child painkilling medicine before taking part in the study, five continued to not use analgesics during the
trial (active drops, n = 2; placebo, n = 1; and usual care, n = 2).
Considering the number of doses of oral analgesic that the children were receiving over the 8 days, there
were no clear differences in the two-group study (Figure 5). In the three-group study, children allocated to
the active drops appeared to take fewer doses than their placebo and usual-care counterparts (see Figure 5).
However, these observed differences were consistent with chance (Table 12).
Parents were also asked if they had given their children any other painkilling remedies. Only one additional
treatment was reported for one child: xylometazoline (Otrivine, GlaxoSmithKline) nasal drops over 2 days.
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FIGURE 4 Mean pain scores by day and group, combining the two- and three-group children and including only
those with full 8 days of data on ear pain.
TABLE 11 Secondary analysis: analgesic consumption, by group
Group
Treatment arm, n/N (%)
OR (95% CI) p-value OR (95% CI)a p-valueaActive drops Placebo drops
Analgesic
consumption
8/9 (89) 6/7 (86) 1.33 (0.07 to 25.91) 0.849 1.21 (0.04 to 34.00) 0.911
Ibuprofen 4/9 (44) 3/7 (43)
Paracetamol 6/9 (67) 6/7 (86)
OR, odds ratio.
a Adjusted for the parent-reported pain score at consultation.
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Secondary outcome: overall symptom burden
For a first exploration of symptom burden, each child’s scores (high scores indicate greater severity,
maximum score of 36 on each day) on each of the symptom measures were added together to give a total
for each of the 8 days following recruitment. An ‘area under the curve’ approach (broadly equivalent to
taking the average score for each child over the 8 days) was taken, with the resulting scores being
positively skewed (Figure 6) and so were transformed (by taking the square root) to allow analysis with
linear regression.
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FIGURE 5 Analgesic consumption up to day 8 for the two- and three-group studies. The box and whisker plots
show the distributions of analgesic consumption. The box represents the IQR, the line within the box is the median,
the upper and lower ‘whiskers’ are defined as the 75th percentile+ 1.5 × IQR and the 25th percentile – 1.5 × IQR,
respectively. The dots outside these ‘whiskers’ are the outliers observed in the data. IQR, interquartile range.
TABLE 12 Secondary analysis: number of doses of oral analgesic, by group
Group
Treatment arm, median (IQR); n
Difference in meansa (95% CI) p-valueaActive Placebo
Number of doses 2.0 (1.0–5.0); 9 6.5 (2.0–9.0); 6 –0.54 (–1.86 to 0.787) 0.397
IQR, interquartile range.
a Calculated using the square root of the number of doses.
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For both the two- and the three-group studies, the active drops appeared to lead to a faster resolution
of symptoms, and so a lower symptom burden over the 8 days (see Figure 6), with modest evidence in
support of these differences (Table 13).
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FIGURE 6 Mean symptom burden in the two-group [(a) and (b)] and three-group studies [(c), (d) and (e)].
TABLE 13 Secondary analysis: overall symptom burden over 8 days, quantified as the area under the curve,
by group
Treatment arm (study) Symptom burden, median (IQR); n Difference in meansa (95% CI) p-valuea
Active drops (three-group) 15.8 (8.5–21.5); 10 Comparison
Placebo drops (three-group) 24.5 (10.5–50.5); 7 1.81 (–0.28 to 3.90) 0.085
Usual care (three-group) 28.5 (14.0–42.0); 9 1.35 (–0.13 to 2.84) 0.072
Active drops (two-group) 11.5 (5.8–33.5); 32 Comparison
Usual care (two-group) 30.3 (6.3–45.0); 28 1.14 (–0.20 to 2.49) 0.094
IQR, interquartile range.
a Calculated using the square root of the area of the curve.
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Secondary outcome: overall illness duration
Children in the active group appeared to be recovering at a faster rate than those in the usual-care group
(Figure 7), but this difference was consistent with chance (Table 14). There was no evidence against the
proportional hazards assumption.
Secondary outcome: time to antibiotic consumption
This measure was only reported for 15 children across the two studies, with no reports for some groups;
consequently, the data are uninformative and not presented here.
Secondary outcome: adverse events
There was one serious adverse event experienced during the trial as a result of which a child was admitted
to hospital due to breathing issues. The child was discharged from hospital the next day and the parent
continued to complete the questionnaire. This child was allocated to the usual-care group, and so the
event can be considered as unrelated to the ear drops.
0.00
0 1 2 3 4
Time (days)
Pr
o
p
o
rt
io
n
 w
it
h
 u
n
re
so
lv
ed
 p
ai
n
5 6 7 8
0.25
0.50
0.75
1.00
No drops
Active drops
Treatment arm
FIGURE 7 Kaplan–Meier curve for the time to recovery from pain in the two-group trial. Time to recovery (score = 0).
TABLE 14 Overall duration of pain
Treatment arm (study) Pain duration, median (IQR); n Hazard ratio (95% CI) p-value
Active drops (three-group) 3 (3–5); 10 Comparison
Placebo drops (three-group) 2 (2–4); 7 1.70 (0.61 to 4.75) 0.31
Usual care (three-group) 3 (2–6); 9 0.94 (0.38 to 2.61) 0.90
Active drops (two-group) 3 (2–5); 34 Comparison
Usual care (two-group) 4 (3–Xa); 31 0.62 (0.34 to 1.11) 0.11
IQR, interquartile range.
a Missing 75th percentile owing to large proportion of censoring at 8 days.
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At the end of the week, parents were asked to report any new or worsening symptoms, and six reports
were made. For the active drops group, these included a head cold (moderate) and chickenpox (mild).
Neither of these symptoms was thought to be related to the drops. For the usual-care group, there were
reports of ringing in the ears (mild); a sore, snotty and bleeding nose (moderate); problem with balance
(moderate); and itching around the neck (moderate). The last two symptoms were experienced by the
same patient. No new or worsening symptoms were reported for the placebo drops group.
Secondary outcome: parent satisfaction
When parents were asked if they were satisfied with the trial ear drops, 93% (27/29) of parents receiving
active drops in the two-group trial said that they were satisfied and 7% (2/29) of parents reported that
they were neither satisfied nor dissatisfied. Parents of children allocated to active drops in the three-group
trial reported 90% (9/10) satisfaction, with 10% (1/10) reporting that they were neither satisfied nor
dissatisfied. Only 57% (4/7) of parents with children allocated to placebo drops reported satisfaction,
with 29% (2/7) reporting that they were neither satisfied nor dissatisfied and 14% (1/7) reporting that
they were not satisfied.
In the three-group trial, parents of children recruited to the active or placebo drops were asked on day 8 if
they thought that their child was taking the painkilling ear drops. In the active group, 60% (6/10) thought
that their child was taking the painkilling ear drops, and in the placebo group 29% (2/7) thought that
they were.
When asked if they would use the drops if they were to be available over the counter, all parents in the
two-group trial said ‘Yes’, with 69% in the active group saying that they would take them without GP
advice compared with 50% in the usual-care group. Of the 26 children recruited in the three-group trial,
two parents said that they would not use the drops if they became available; both were in the blinded
placebo group. When asked what they would use in the future, 79% (23/29) of those in the active group
of the two-group trial said just the trial drops, compared with 40% (4/10) of those active group patients
in the three-group trial; these results are given in Figure 8. When comparing the answers to this question
between those who gave their children antibiotics during the study and those who did not, it was found
that those who gave antibiotics were more likely to say that they would use antibiotics again (20%, 3/15)
than those who had not (3%, 2/69).
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FIGURE 8 By trial group: what would you want to use for your child for a similar illness in the future?
DOI: 10.3310/hta23340 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 34
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Sensitivity analyses
Per-protocol analysis
The trial team, together with the Data Monitoring Committee, defined compliance as taking study
medication on ≥ 50% of the days that they reported pain. The per-protocol analysis excluded patients not
achieving this level of compliance.
Overall, 78% of parents reported using the drops on all of the days when their children reported pain.
There was only one child who did not comply at least 50% of the time, and this was the one child in the
active drops group (two-group study) who consumed antibiotics. When we repeat the analysis without this
child, the evidence of reduced antibiotic use in the active drops group remains (Table 15).
Sensitivity analysis: missing data imputed under best- and worst-case scenarios
Twenty-two children withdrew or were lost to follow-up before completing 8 days of reporting, and their
antibiotic consumption status was therefore unknown. For a best-case scenario, the 11 children in the
active group were assumed to have completed the trial without taking antibiotics, and the eight children
in the usual-care group were assumed to have taken antibiotics at some point during the 8-day follow-up.
For the worst-case scenario, the 11 children in the active group were assumed to have taken antibiotics and
the eight children in the active drops group were assumed to have completed follow-up without consuming
antibiotics. These assumptions are at the two extremes and the results, as expected, show that the best-case
scenario strengthens the evidence for reduced antibiotic use in the active drops group, whereas the
worst-case scenario weakens the evidence such that a reduction in antibiotic use is no longer clearly
apparent (Table 16).
TABLE 15 Sensitivity analysis: per-protocol analysis excluding from the two-group study, one child who did not
meet the compliance criterion for the study medication – antibiotic consumption, by group
Group
Treatment arm, n/N (%)
OR (95% CI) p-valueActive drops Usual care
ITT analysis 1/29 (3) 9/30 (30) 0.08 (0.01 to 0.71) 0.023
Per-protocol analysis 0/28 (0) 9/30 (30) 0.04 (0.00 to 0.73)a 0.030a
OR, odds ratio.
a Calculated using a continuity correction of 0.4828.
TABLE 16 Sensitivity analysis with missing data imputed under best- and worst-case scenarios: antibiotic
consumption, by group
Variable
Treatment arm, n/N (%)
OR (95% CI) p-valueActive drops Usual care
Best-case scenario
Two-group trial 1/38 (3) 15/36 (42) 0.04 (0.00 to 0.31) 0.002
Three-group trial 0/12 (0) 4/10 (40) 0.05 (0.00 to 1.29)a 0.071a
Worst-case scenario
Two-group trial 10/38 (26) 9/36 (25) 1.07 (0.38 to 3.04) 0.897
Three-group trial 2/12 (17) 2/10 (20) 0.80 (0.09 to 7.00) 0.840
OR, odds ratio.
a Calculated with a continuity correction of 0.4545.
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Sensitivity analysis: exclusion of children found to be ineligible following allocation
The primary analysis was repeated without two children who were found to be ineligible only after data
collection was complete: one child in the usual-care group of the two-group trial (who had bilateral AOM
and was < 2 years old) and one child in the usual-care group of the three-group trial (who had otorrhoea
in one ear). Table 17 shows the results when these two children were removed from the analysis. After
removing the two ineligible children, the evidence for a reduction in antibiotic use in the active drops
group was strengthened slightly.
Exploratory analysis: reported pain by antibiotic use
For those with pain scores for all 8 days, children who took antibiotics (n = 15) appeared to have higher
pain scores than those who did not take antibiotics (n = 69) during the study (Figure 9). Although the
direction of cause and effect could not be established from these data, it is possible that the use of
antibiotics resulted from the higher pain.
Subgroup analyses
The evidence for subgroup effects is difficult to interpret in the context of low statistical power, which
was the case for this study because of the modest sample size realised and the dimensions investigated
having one subgroup much larger than the other. Consequently, the summary statistics are presented in
Table 18.
TABLE 17 Sensitivity analysis with two children found to be ineligible removed: antibiotic consumption, by group
Antibiotic consumption
Treatment arm, n/N (%)
OR (95% CI) p-valueActive drops Usual care
Two-group trial 1/29 (3) 9/29 (31) 0.08 (0.01 to 0.68) 0.021
Three-group trial 0/10 (0) 2/7 (29) 0.09 (0.00 to 2.84)a 0.171a
OR, odds ratio.
a Calculated with a continuity correction of 0.4118.
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FIGURE 9 Mean pain scores by day and antibiotic consumption, combining the two- and three-group children and
including only those with full 8-day data on ear pain.
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Health economic results
Cost-effectiveness findings
The unit costs of resources are presented in Table 19. There were no substantial differences in the total
costs of health care or parental time off work during days 1–8 (Table 20). The reduction in antibiotic
use among participants allocated to receive active drops leads to only a very small reduction (£0.38) in
antibiotic prescribing costs in the short term. A small number of children had repeat consultations with
their GP, the NHS 111 telephone consultation service or hospital ambulatory care services, but there was
no difference in the cost of this care between groups. The mean number of parent/carer days off work
was similar in the active drops (0.58 days) and usual-care (0.61 days) groups, but varied widely among
respondents (range 0–6 days). Owing to the large variations in repeat consultations and time off work,
the CI around the difference in total costs is wide and includes £0.
TABLE 18 Subgroup variations in the effect of active drops vs. usual care on whether or not children
consumed antibiotics
Subgroup
Treatment arm
Active drops Usual care
N Consumed antibiotics, n (%) N Consumed antibiotics, n (%)
Prior duration of illness
≤ 72 hours 20 1 (5) 23 7 (30)
> 72 hours 9 0 (0) 7 2 (29)
Ear drum visible
Yes 28 1 (4) 30 9 (30)
No 1 0 (0) 0 0 (0)
AOM ear(s)
Unilateral 20 1 (5) 27 8 (30)
Bilateral 8 0 (0) 3 1 (33)
Antibiotic prescribing
Delayed 3 0 (0) 10 7 (70)
None 26 1 (4) 20 2 (10)
TABLE 19 Unit costs of resource valuation
Resource Unit cost Perspective Source of cost
Active drops £3.54 per 15-ml bottle NHS Online pharmacies
Antibiotic £1.17 to £2.34 per prescriptiona NHS BNF22
Paracetamol £0.24 to £0.87 per daya NHS BNF22
Ibuprofen £0.19 to £0.58 per daya NHS BNF22
GP visit £36.00 NHS PSSRU24
NHS 111 £12.26 NHS Evaluation of NHS 111 study report33
Hospital-related services £199.00 NHS PSSRU24
Time off work £539.00 per weekb Societal Office for National Statistics34
PSSRU, Personal Social Services Research Unit.
a Depending on patient age.
b Median gross weekly earnings for full-time employees in the UK.
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Among the 75 children (active drops, n = 38; and usual care, n = 37) with complete data, our findings
suggest that, from a NHS and societal perspective, active drops have the potential to both save money
(£75.07 active drops; £76.92 usual care) and reduce antibiotic prescriptions (2.6%, active drops; 27.0%,
usual care). Restricting the analysis to NHS costs (£12.66, active drops; £11.36, usual care) leads to an
estimated cost of £5.19 per antibiotic prescription avoided, although this is associated with a high degree
of uncertainty [95% CI lower limit (cost saving) undefined to upper limit £110]. The estimate is also
sensitive to the unit cost of Auralgan; in a sensitivity analysis, assuming that the NHS pays the approximate
retail cost of £10.40, the cost per antibiotic avoided increased to £33.43.
Other outcomes
Children in both the active drops and the usual-care groups of the trial had improvements in health-related
quality of life, measured by the CHU-9D, at 2 days after randomisation and further improvements were
observed by day 8 (Table 21). As this questionnaire was completed only for children aged ≥ 5 years, the
sample size is small. However, there is weak evidence that CHU-9D scores were higher (better) among
children in the active drops group at 8 days. There was no difference in the mean number of days off
school or preschool childcare (Table 22).
TABLE 20 Health care and time off work costs, days 1–8, by group
Resource
Treatment arm, mean (SD)
Mean difference
(95% CI) p-valueActive drops (n= 38)a Usual care (n= 37)a
Active drops £3.54 (0) £0 (0)
Antibioticsb £0.06 (0.38) £0.44 (0.80) –£0.38 (–0.67 to –0.10) 0.01
Ibuprofenb £0.44 (0.57) £0.49 (0.62) –£0.05 (–0.32 to 0.23) 0.73
Paracetamolb £0.84 (0.90) £1.17 (1.09) –£0.32 (–0.78 to 0.13) 0.16
GP/NHS 111/ambulatory £7.78 (40.66) £9.27 (44.99) –£1.49 (–21.21 to 18.23) 0.88
Time off work £62.41 (75.74) £65.55 (141.55) –£3.14 (–55.20 to 48.91) 0.91
Total £75.07 (99.47) £76.92 (154.94) –£1.85 (–61.61 to 57.91) 0.95
a Analysis on health care and time off work was conducted using complete data.
b Dose adjusted for age.
TABLE 21 The CHU-9D scores, by group
Group
Treatment arm, mean (SD); n
Mean difference
(95% CI) p-valueActive drops Usual care
Baseline 0.696 (0.121); 21 0.657 (0.148); 19 0.039 (–0.047 to 0.125) 0.367
Day 2 0.829 (0.146); 17 0.807 (0.154); 15 0.023 (–0.086 to 0.131) 0.672
Day 8 0.983 (0.030); 21 0.923 (0.109); 15 0.060 (0.010 to 0.110) 0.021
TABLE 22 Days off school or preschool childcare, by group
Group
Treatment arm, mean (SD); n
Mean difference
(95% CI) p-valueActive drops Usual care
Number of days 0.95 (0.92); 39 0.91 (1.29); 38 0.04 (–0.47 to 0.55) 0.873
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Qualitative data results
Number and characteristics of parents
Three parents were interviewed, all of whom had taken part in the three-group trial. Table 23 displays
characteristics of the parents and their children, including the trial participant child.
Owing to the primary aim of the qualitative evaluation (examining parents’ views and experiences of
active, placebo and usual-care groups of the trial), interviews did not proceed until the three-group trial
started. Six trial parents were contacted to take part in the qualitative interview; one did not respond,
two agreed but could not conduct the interview within the study time period, and three agreed and took
part in an interview. Owing to limited number of interviews, data saturation was not reached.
Themes developed from the analysis are described below with the use of verbatim quotes.
Views and experiences of trial
Parents spoke positively about the trial, saying that they thought it was a good idea. All the parents were
pleased to be part of the trial and welcomed being invited to take part:
It sounded great and actually . . . it’s such a great idea.
PA01
I was quite open to it.
PA02
I think that the trial was good.
PA03
Parents demonstrated a good understanding of the aims of the trial:
Well I guess it was to test this local, local anaesthetic stuff on kids, um to see if it helped um kids that
regularly suffer from ear pain, um whether it just you know to sort of um, kind of um avoid using
antibiotics in the future.
PA03
TABLE 23 Interviewee characteristics
Parent
Interviewee
PA01 PA02 PA03
Number of children 3 1 3
Age range of children (years) 2–11 7 3–6
Age of participating child (years) 2 7 3
Previous history of AOM Siblings and study child Study child Siblings
Active or placebo drops Active Placebo Placebo
Index of multiple deprivation decilea 4 7 8
a Where 1 is the least deprived and 10 is the most deprived.
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When deciding to participate in the trial, perceived safety of the medicine was as important to the parents
as the strength of the parents’ faith and trust in doctors and ‘scientists’ (PA02). Although safety was a
concern, information provided within the information sheet and by practice staff during discussions at the
point of recruitment, about established safety of use of the treatment, calmed any fears. Parents also felt
comforted by having choice and control over whether or not the drops were administered and when:
I think it you know they [drops] were proven to help I was told in Australia and I thought well if
they’re available elsewhere . . . and they’re safe, I’m quite happy. My boy was quite happy . . . to do it,
so yeah I was quite happy.
PA02
I thought it [the CEDAR trial] was good . . . and I always think it’s as long as it’s not, you know like it’s
a safe trial then I’m perfectly happy with that yeah.
PA03
I mean like I think that the trial was good, in that you know it did mention that if you don’t want to
take the ear drops, then you can just put zero on that day . . . that was kind of a very positive kind of
thing for me because you know I wouldn’t, I didn’t feel the pressure to have to like to do it if it was
really just she was really hard to hold down or something, I’d just like right that’s that done and not
to have to have committed to doing it for five or six or seven, do you know what I mean like kind of
kept, that was kind of a choice which I kind of yeah appreciated.
PA03
Parents also felt that, as the drops were being externally applied as opposed to an oral medication,
any risk was lowered and it was safer for the child to use. This added to their comfort for their child being
involved in the trial:
I guess because it wasn’t like they were taking medicine orally, they were kind of, it was sort of an external
thing that made me think that it was probably safer . . . but it [sic.] they were giving me something, a trial
that was a medicine you consumed, then maybe I’d be a bit more concerned about that.
PA03
Parents felt that they had sufficient information to enable them and their child to take part in the trial.
Information provided through the information sheet and by the study team was clear and well received.
Parents appreciated that they could contact the study team with any queries. One parent used this
resource to check whether or not they needed to continue with the drops when they felt that they did not
need to any more:
It [study information] was fairly straightforward really, it just – it’s quite – it was pretty self-explanatory
. . . The only thing was I checked um about like how long to use them once he’s got better, if you
think – once you felt they’d got better . . . she [research nurse] was really good and she just messaged
me back and just said that – carry on using it probably for like a couple of days after, like you would
do with anything really, you know.
PA01
Parents interviewed did not use the online video that was available either because they felt that they did
not need it as they already had sufficient information or did not have the time. The length of time and
detail provided by the GP was important to parents and welcomed:
He [GP] was really good and really thorough about everything really . . . He went through it all of it
actually . . . I think we were in there for ages, bless him, it made him very late . . . but he was really
good and went through everything and checked, like went through it all with me.
PA01
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Reasons for and experiences of consulting
Parents all consulted the GP because of their child being upset and in pain. One parent commented that
because the child had a history of previous serious ear infection resulting in hospitalisation, she wanted
‘piece [sic.] of mind’ (PA01). Parents had no expectations of the consultation other than that the doctor
would check the ear(s) and there would be discussion about any treatment. The main concern was to ease
the child’s pain, whether by use of antibiotics, as in the past, or by other means:
Really like that if it was an ear infection and it, um – that he would get antibiotics possibly, if that was
right – it’s really hard ‘cause there’s no – I wouldn’t say I’d go for antibiotics. But it’s a discussion you
would have with the doctor.
PA01
Thing was he was in pain, I just wanted him not to be in pain you know.
PA02
There’s nothing worse than earache is there in kids?
PA02
Parents did not express an expectation of antibiotics from the consultation even if their child had used
them in the past and were aware of the issue of antibiotic resistance:
You don’t just want to give them antibiotics because they get resist – you know, then the resistance
come up and stuff.
PA01
I didn’t really [expect antibiotics], I don’t really, I’m not overly keen on the idea of constantly giving
kids antibiotics so you know as long as I don’t think that there’s any danger of the infection getting
worse, then I’d prefer to let yeah, I’d prefer to them to sort of recover by themselves yeah.
PA03
Parents were aware of attempts to decrease antibiotic use and embraced advice provided by the GP
concerning their use. GPs had explained, within the initial trial consultation, that the type of infection
being experienced would clear up on its own and that antibiotics may be of little use. They felt this was a
discussion that needed to happen between themselves and the doctor and that they would be happy with
what the doctor recommended:
I wouldn’t always say I’d go for antibiotics. But it’s a discussion that you would have, I guess, with the
doctor and see actually knowing his history that possibly antibiotics might be the right course. But if
it’s not that bad.
PA01
They [drops] help with pain with earache because if it’s a viral earache then antibiotics don’t
necessarily work and the earache will go away on its own.
PA02
Well the doctor then, he told my husband that they were trying to not use antibiotics anymore and to
leave it to clear up itself . . . I was happy with that to be honest . . . I mean I’d usually just take the
doctor’s advice and go with what they think is best, so on that account I was like right if they think it’s
going to clear up without antibiotics, that’s fine.
PA03
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However, being able to have a delayed antibiotics prescription meant that they felt reassured when given the
drops in case the child’s condition worsened. Parents did not use this prescription as they felt administering
the trial drops was sufficient:
He [the GP] put my mind a bit more at ease because he gave me the delayed prescription . . . Because
that was my only concern, that actually sometimes with [child’s name] with his ear infections, they go
from nothing to sort of like really bad, that we could get him a prescription without having to go back
to the doctor if needed.
PA01
Views and experience of treatments
Pain relief for the child was important to the parents and was discussed most when exploring experience
of using the drops. All parents believed that the drops that they had received had relieved pain levels
within the first day and parents (including those who had received the placebo drops) reported reduced
use of other forms of pain relief, for example paracetamol (Calpol®, Johnson & Johnson Limited). When
asked whether they thought they had the active or the placebo drops, all parents felt that, because of the
quick reduction in pain and not using additional pain relief, they had the active drops:
Obviously it was uncomfortable ‘cause he didn’t really like the drops being put in. But there wasn’t a
lot of pain, he didn’t seem in pain with it and we didn’t need to use much Calpol . . . it seemed to
clear up quite quickly.
PA01
But he did say, he said his ear felt I don’t know after about 20 minutes, it wasn’t as painful as what it
was before he had the drops . . . whereas he’d had an ear infection, earache before, it was a constant
pain. And I hadn’t been giving him Calpol, so I couldn’t say that was taking the pain away.
PA02
It became apparent she was fine, like it got a bit, it became apparent that her ear wasn’t hurting as
much, she was like after you know a couple of days you could touch her ear without her complaining
whereas before you couldn’t even touch her without her crying.
PA03
Some parents discussed difficulties administering the drops as children were young and did not like the
drops, or that parents had problems with the size of the bottles or drops:
The actual droplet thing was quite big for his ear . . . I think if it was a different bottle with a different,
much smaller nozzle . . . it would have been a bit easier, because they were quite gloopy the drops were.
So, I think if you could have got then [sic.] in, the droplet was just a bit too fat, do you know what I mean?
PA02
Well it was fine, if I could get it into her ear, to begin with it was quite hard because she’s only 3, she
didn’t, she doesn’t like taking any type of medication or put cream on even you know, she’s awkward
with everything, so I had to you know we had to kind of hold her in position to get the ear drops in
her ear . . . so that was quite awkward to be honest, I know they said you take up to 12 doses a day
or something, but we could barely get in that many to begin with because of just the fight and stuff.
PA03
Parents compared the use of the drops with previous experiences of antibiotics and felt the drops were
beneficial and would be happy to use them for pain relief:
With the drops he appeared that the pain subsided whereas with antibiotics it takes a couple of days
for it to start kicking in, so your topping them up with you know Calpol.
PA02
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Yeah I probably would [use drops] because you know if the doctor’s saying to me you know if he has
antibiotics, it’s only going to take a day off the pain, you know if he is going to be pain free for just
one less day . . . instead of pumping, instead of putting antibiotics in, if I could put just a painkiller and
it would take the pain away . . . if the infection if going to clear up on its own anyway, I think it would
be good to have a painkiller for him . . . to take the pain away.
PA02
Parents with the confidence that the benzocaine/phenazone drops had reduced pain in their children
would be happy to buy the drops from a pharmacy (over the counter) rather than consult the GP. This was
on the premise that a pharmacist would be available for advice and information:
You know you’re giving it to a child, I think a little bit of advice from the pharmacist, how many times
you can give it in a day and you know if the pain doesn’t go away within so many days you know
contact your doctor sort of thing.
PA02
I’d probably like to ask the pharmacist that you know what they thought, and you know if they knew
about the product and everything, it would just be sort of how to use it, you know not to overdose on
it, just kind of basic information you get on most medicines.
PA03
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Chapter 4 Discussion
Summary of main findings
Despite the CEDAR trial falling short of its sample size target, and demonstrating a lower than expected
antibiotic consumption rate, the results provide evidence of a reduction in antibiotic consumption with the
use of anaesthetic–analgesic ear drops compared with children who were not provided with ear drops.
The primary analysis (active drops vs. usual care) found modest evidence of a difference between groups when
combining the results of the two- and three-group studies, with 11 out of 38 (29%) children in the usual-care
group consuming antibiotics, compared with 1 out of 39 (3%) children in the anaesthetic–analgesic drops
group. This represents an 87% reduction in the odds of consuming antibiotics (odds ratio 0.13, 95% CI
0.01 to 1.13). If this reflects a true effect of the ear drops, the most likely explanation for reduced antibiotic
consumption is reduced pain. However, secondary analyses showed both placebo (glycerol) and active drops
to be superior to no drops for pain relief at day 2. The former could be explained by the placebo effect or a
soothing anti-inflammatory effect of glycerol. Secondary outcome measures provided modest evidence of
reductions in oral analgesic consumption, symptom burden and illness duration in the active drops group
compared with the usual care group.
Our economic analyses demonstrated that the use of active drops is unlikely to reduce medication costs in
the short term, primarily because antibiotics are cheap. The more substantial economic benefits are likely
to come in the longer term, via reduced antimicrobial resistance. Nevertheless, the ‘cost per antibiotic
avoided’ of active drops is low and, if parental productivity costs are included in the analysis, it may even
save money. Weak evidence was found that active drops improved health-related quality-of-life scores,
measured by the CHU-9D at 8 days.
Interviews conducted with three participating parents revealed their views and experiences of AOM, its
treatment and the CEDAR trial. The study aim was viewed positively by parents, who felt the treatment
of pain to reduce the use of antibiotics was a good idea and who were happy for their child to participate.
Parents’ main reason for taking their child to the doctor was that their child was upset and in pain and
they wanted pain relief for their child. Parents did not express any preconceptions of whether or not the
child should receive antibiotics and were happy to discuss treatment options with the doctor. Parents
spoke positively about the trial drops, and all believed that they reduced pain in the child, although this
was also the case for parents whose children received placebo drops. Parents stated that they would be
happy to purchase the drops over the counter from a pharmacy, provided that pharmacist advice
was available.
Strengths and weaknesses
The CEDAR trial was a pragmatic RCT conducted in UK primary care practices; allocation was concealed
during recruitment and around 80% of parents provided full data on their child’s antibiotic consumption
during the key 8-day follow-up period. However, the study was subject to a number of limitations.
The clear weaknesses of the CEDAR trial were the small sample size achieved (particularly with the planned
three-group study), not being able to collect data at the planned 3-month follow-up point and not being
able to commence recruitment in emergency departments as planned. Although comparisons of the raw
data suggest a substantial treatment effect on antibiotic consumption, the results need to be interpreted
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with caution as estimates are imprecise and we are not able to confirm the probable mechanism through
reduced pain. This weakness is likely to be purely one of low statistical power; although the study did close
early, this is unlikely to have caused bias as early closure did not curtail the planned recruitment period
and was a decision of the funder, who was unaware of the findings of the confidential interim analysis
(although it had been made aware of the lower than expected antibiotic prescription rate across the
three study groups combined). The lack of data at the 3-month follow-up means that the safety of the
intervention in the period immediately after the infection, and the incidence of recurrent infection,
remain unknown.
We observed a greater proportion of children in the usual-care group than in the drops groups who received
a delayed prescription for an antibiotic. We had intended for children to receive these prescriptions prior to
being allocated to a study group, although we cannot guarantee that this always occurred and, in hindsight,
whether or not the child had received a delayed prescription should have been included in the information
provided when logging the child into the study, in preparation for allocation to a study group. Those children
provided with a delayed prescription were more likely to consume antibiotics during the 8-day follow-up;
our prespecified primary analysis attempted to control for any confounding through this route. Of the small
number of children in one of the drops groups who received a delayed prescription, none subsequently
consumed antibiotics; this suggests that if receipt of a delayed prescription been equally low in the usual-care
group, then this may have reduced antibiotic consumption in that group and hence reduced the difference
in antibiotic consumption between study groups. However, taking a different view, although the intention
had been to standardise antibiotic prescribing across the study groups, what actually happened in the
trial would be closer to routine clinical practice, in which GPs might prescribe fewer antibiotics if they can
provide anaesthetic–analgesic ear drops instead, with the lower prescription rate resulting in lower antibiotic
consumption.
In fact, antibiotic consumption was already lower than anticipated in the usual-care group, potentially
owing to the overcautious exclusion of children considered to need immediate antibiotics, to reduced use of
delayed prescriptions by participating GPs who are perhaps already keen to reduce antibiotic consumption,
or to informed consent procedures including the study rationale, which would have given parents the
chance to opt out if they were keen to use antibiotics (the planned but unrealised observational cohort
would have addressed this) or may have convinced some parents of the unsuitability of antibiotics for the
treatment of AOM ear pain.
The larger number of participating children were recruited to the two-group study, which did not include
the placebo drops group and so could not provide reliable evidence that the anaesthetic–analgesic drops
were reducing antibiotic consumption through a painkilling mechanism. However, despite the modest
sample size realised, the study does provide weak evidence that parents of children presenting to primary
care with ear pain due to AOM find ear drops to be an acceptable treatment and are consequently less
likely to use antibiotics. It seems unlikely that a different pattern of results would have been observed had
children in the drops groups been more often provided with a delayed prescription for antibiotics, and
indeed the study shows that parents of children in the drops group found it acceptable not to receive such
a delayed prescription.
From the perspective of the economic analysis, as Auralgan is not in the BNF,22 it is currently unclear how
much the NHS would pay for it if GPs were to prescribe it. Plausible assumptions have been made based on
drug prices in other high-income countries and potential NHS discounts. However, if the actual procurement
price were higher, the intervention would be less cost-effective than we have estimated. Owing to falling
short of the recruitment target, the evidence of a reduction in health-care use up to 8 days was very weak,
and with the review of medical records not going ahead we were unable to evaluate whether or not the
possible reduction in health-care use might have been amplified over a 3-month period.
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The strengths of the qualitative study are that it included parents who took part in the trial and it was
therefore able to provide views and experiences from those directly involved. Reported themes were
present across all interviews, strengthening their standing. All parents had previous experience of children
with AOM and treatment and were therefore well placed to comment on whether or not the treatment
was acceptable and whether or not they believed it worked. The main limitation is the small number of
interviews conducted. Although more were planned, only three interviews with trial parents could be
conducted within the timeframe of the three-group trial. This does provide useful insight into how parents
experienced the trial and using the trial drops. However, caution needs to be exercised when taking
findings forward. Views were captured only from those who agreed and continued to participate in the
trial. Further interviews need to be conducted with a larger number of parents to determine whether
or not findings continue to be prevalent and important. Further issues including divergent views and
experiences may also be uncovered. As the sample was small, it was not possible to utilise a maximum
variation approach and parents with different characteristics, for example socioeconomic backgrounds,
child age, trial centre and trial group, need also to be interviewed. Owing to the delay with the trial it was
also not possible to capture views and experiences of health-care professionals. Therefore, important
insights into how the people directly involved in the care of the children and who were key to successful
trial implementation were not gleaned. Future research needs to capture the views and experiences of
health-care professionals from a range of trial sites.
Comparison with other literature
No new randomised studies of anaesthetic–analgesic ear drops have been published since the last
Cochrane review in 2011. The three previous studies have assessed the effectiveness of topical analgesia
against placebo in relieving pain due to AOM;11–13 all were included in the Cochrane review (updated 2011),
which concluded that ‘the evidence from [these] RCTs is insufficient to know whether ear drops are
effective’.14 These studies address the efficacy of drops for pain and not the impact on case management
with antibiotics; none of the trials included an economic evaluation. That said, pain relief is important
to parents, and this emerged in the qualitative interviews completed for this study. In a post hoc and
unblinded comparison of ear pain between this study’s active and usual-care groups, there was moderate
evidence to suggest that active ear drops reduced ear pain, and this was strengthened after adjusting for
baseline ear pain (at consultation). After adjustment, the combined mean difference was almost 2 points
on the 0- to 6-point scale. In the analysis of pain relief following first instillation of drops in the small
sample of 17 patients, there was no evidence to suggest that pain was reduced in active compared with
placebo drops groups. However, both unadjusted and adjusted results were in favour of the active drops;
those in the active groups had pain scores that were, on average, 0.73 points lower than in the placebo
group. Thus, despite the small sample size, the present study may make a further contribution to the
Cochrane review.
There is a well-recognised variation in prescribing rates for otitis media: the median rate being 60%, while
in the highest decile of prescribing practices the figure is 90%.1 A previous study in AOM investigated
consumption,20 finding that 24% of children consumed antibiotics following a delayed prescription,
compared with 33% in this usual-care group.
Our analyses suggest that anaesthetic–analgesic drops might increase medication costs during the acute
episode. However, the wider societal costs of antimicrobial resistance were not quantified here. A literature
review concluded that current estimates of the costs of resistance are likely to be underestimates and that
an accurate forecast of costs may not be possible.21 A recent trial evaluating the use of antibiotics in lower
respiratory tract infections demonstrated that strategies to avoid antibiotic use become dramatically more
cost-effective once the costs of resistance are included in the estimate.35
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Implications for clinical practice and research
Tackling antibiotic resistance is an international priority and reducing unnecessary antibiotic use for
self-limiting illness is one potential mechanism to address this. This study suggests that substantial reduction
in antibiotic use might be achieved in AOM in children by combining a no or delayed prescribing strategy
with anaesthetic–analgesic ear drops.
A benefit of the analgesic effect of the active drops remains unproven when compared with placebo,
although both active and glycerol drops may have important pain-relieving properties. Further research
is needed to establish if effects are mediated by the active ingredients or if they could be achieved using a
non-pharmacologically active oil.
Conclusion
This study has provided evidence that anaesthetic–analgesic ear drops result in a substantial reduction in
antibiotic consumption in children presenting to primary care with AOM. The small number of children
allocated to the placebo drops group was insufficient to establish whether or not the anaesthetic–analgesic
ear drops reduced pain. Replication of these findings in a larger study would give greater confidence for
informing clinical guidelines, would establish the safety of the intervention beyond the first 8 days and,
if the mechanism of action can be established, may allow refinements to the intervention.
DISCUSSION
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Appendix 1 Recruitment to the CEDAR trial
0
50
100
150
200
250
300
350
400
450
500
550
O
ct
o
b
er
 2
01
6
N
u
m
b
er
 o
f 
ch
ild
re
n
 r
an
d
o
m
is
ed
N
o
ve
m
b
er
 2
01
6
D
ec
em
b
er
 2
01
6
Ja
n
u
ar
y 
20
17
Fe
b
ru
ar
y 
20
17
M
ar
ch
 2
01
7
A
p
ri
l 2
01
7
M
ay
 2
01
7
Ju
n
e 
20
17
Ju
ly
 2
01
7
A
u
g
u
st
 2
01
7
Se
p
te
m
b
er
 2
01
7
O
ct
o
b
er
 2
01
7
N
o
ve
m
b
er
 2
01
7
D
ec
em
b
er
 2
01
7
D
ec
em
b
er
 2
01
7
Ja
n
u
ar
y 
20
18
M
ar
ch
 2
01
8
M
ar
ch
 2
01
8
A
p
ri
l 2
01
8
M
ay
 2
01
8
Ju
n
e 
20
18
Projected RCT recruitment –
all centres (cumulative,
two- plus three-group 
trials)
Actual RCT recruitment –
all centres (cumulative,
two- plus three-group 
trials)
Actual RCT recruitment –
all centres (cumulative,
two-group trial only)
Actual RCT recruitment –
all centres (cumulative,
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Sample size for two-group trial (90% power) = 314
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Trial month/year
Sample size for three-group trial (90% power) = 501
FIGURE 10 Projected and actual recruitment to the CEDAR trial: October 2016 to April 2017. Between October and
December 2016, prior to the supply of IMP running low, randomisations to the two-group study reached target.
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